



(11) **EP 2 988 668 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
24.07.2019 Bulletin 2019/30

(21) Application number: **14789048.7**

(22) Date of filing: **24.04.2014**

(51) Int Cl.:
A61B 5/05 (2006.01) **A61B 5/00** (2006.01)
A61B 6/00 (2006.01) **A61B 5/055** (2006.01)
G01R 33/28 (2006.01) **G01R 33/48** (2006.01)
G01R 33/56 (2006.01) **G06T 7/00** (2017.01)

(86) International application number:
PCT/IB2014/060981

(87) International publication number:
WO 2014/174480 (30.10.2014 Gazette 2014/44)

(54) **MAGNETIC RESONANCE MAPS FOR ANALYZING TISSUE**

MAGNETRESONANZKARTEN ZUR ANALYSE VON GEWEBE

CARTES DE RÉSONANCE MAGNÉTIQUE POUR ANALYSE DE TISSU

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: **24.04.2013 US 201361815343 P**

(43) Date of publication of application:
02.03.2016 Bulletin 2016/09

(73) Proprietors:
• **Tel HaShomer Medical Research Infrastructure and Services Ltd. 5262000 Ramat Gan (IL)**
• **Ramot at Tel-Aviv University Ltd. 6139201 Tel-Aviv (IL)**

(72) Inventors:
• **MARDOR, Yael 42655 Natania (IL)**
• **ZACH, Leor 76606 Rehovot (IL)**
• **GUEZ, David 62646 Tel-Aviv (IL)**
• **LAST, David 93117 Jerusalem (IL)**
• **DANIELS, Dianne 47235 Ramat-HaSharon (IL)**

(74) Representative: **Boult Wade Tennant LLP 5th Floor, Salisbury Square House 8, Salisbury Square London EC4Y 8AP (GB)**

(56) References cited:
WO-A1-2013/057697 US-A1- 2003 050 552
US-A1- 2005 171 423 US-A1- 2006 226 836
US-A1- 2010 106 007 US-A1- 2010 172 842

- **AICHER ET AL: "Contrast-enhanced magnetic resonance imaging of tumor-bearing mice treated with human recombinant tumor necrosis factor alpha.", CANCER RESEARCH, vol. 50, no. 22, 1 November 1990 (1990-11-01), pages 7376-7381, XP055064732, ISSN: 0008-5472**
- **LEOR ZACH ET AL: "Delayed Contrast Extravasation MRI for Depicting Tumor and Non-Tumoral Tissues in Primary and Metastatic Brain Tumors", PLOS ONE, vol. 7, no. 12, 14 December 2012 (2012-12-14), page e52008, XP055320974, DOI: 10.1371/journal.pone.0052008**
- **MANNELLI ET AL: "Evaluation of nonenhancing tumor fraction accessed by dynamic contrast-enhanced MRI subtraction as a predictor of decrease in tumor volume in response to chemoradiotherapy in advanced cervical cancer", AMERICAN JOURNAL OF ROENTGENOLOGY, AMERICAN ROENTGEN RAY SOCIETY, US, vol. 195, 1 August 2010 (2010-08-01), pages 524-527, XP003031152, ISSN: 0361-803X, DOI: 10.2214/AJR.09.3437**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 988 668 B1

- AICHER ET AL.: 'Contrast-enhanced Magnetic Resonance Imaging of Tumor-bearing Mice Treated with Human Recombinant Tumor Necrosis Factor Alpha' **CANCER RESEARCH** vol. 50, 01 November 1990, pages 7376 - 7381, XP055064732
- ISRAELI ET AL.: 'The Application of MRI for Depiction of Subtle Blood Brain Barrier Disruption in Stroke' **INT. J. BIOL. SCI.** vol. 7, no. 1, 26 December 2010, pages 1 - 8, XP003031151
- MANNELLI ET AL.: 'Evaluation of nonenhancing tumor fraction accessed by dynamic contrast as a predictor of decrease in tumor volume in response to chemoradiotherapy in advanced cervical cancer' **AJR** vol. 195, 01 August 2010, pages 524 - 527, XP003031152
- NEWATIA ET AL.: 'Subtraction Imaging: applications for Nonvascular Abdominal MRI' **AJR** vol. 188, 01 April 2007, pages 1018 - 1025, XP003031153
- DING ET AL.: 'Contrast-Enhanced Subtraction Harmonic Sonography for Evaluating Treatment Response in Patients with Hepatocellular Carcinoma' **AJR** vol. 176, 01 March 2001, pages 661 - 666, XP003031154
- LEWIN ET AL.: 'Dual-Energy Contrast enhanced Digital Subtraction Mammography: Feasibility' **RADIOLOGY** vol. 229, 01 February 2003, pages 261 - 268, XP008045080
- POWERS ET AL.: 'The High-Resolution, Three-Dimensional Solution Structure of Human Interleukin-4 Determined by Multidimensional Heteronuclear Magnetic Resonance Spectroscopy' **BIOCHEMISTRY** vol. 32, 01 January 1993, pages 6744 - 6762, XP002304542

DescriptionFIELD AND BACKGROUND OF THE INVENTION

5 **[0001]** The present invention relates to method and apparatus for producing magnetic resonance (MR) maps and, more particularly, but not exclusively to using such maps to identify and study tumors.

[0002] MRI is considered the gold standard imaging modality for the brain. Although MRI provides high resolution and good sensitivity, standard MR sequences still suffer of low specificity especially in the case of tumors, e.g., brain tumors (during/after treatment).

10 **[0003]** Gliomas are the most common malignant primary brain tumors in adults, with an annual incidence of 4-5 per 100,000 people (Central Brain Tumor Registry; Wen and Kesari, 2008).

[0004] The standard of care for glioblastoma includes surgery, chemotherapy during and after radiotherapy. The use of temozolomide (TMZ) both during radiotherapy and for six months post radiotherapy results in a significant increase in median survival with minimal additional toxicity. This treatment regime is now standard for most cases of glioblastoma where the patient is not enrolled in a clinical trial.

[0005] Temozolomide seems to work by sensitizing the tumor cells to radiation. The U.S. Food and Drug Administration approved Bevacizumab (Avastin) to treat patients with glioblastoma at progression after standard therapy based on the results of 2 studies that showed Bevacizumab reduced tumor size in some glioblastoma patients.

20 **[0006]** Treatment efficacy assessment of high-grade gliomas is currently based on overall survival or, more commonly in patients with recurrent disease, on progression-free survival (PFS) (Wong et al, 1999; Lamborn et al, 2008), determined by radiographic response. The Macdonald criteria (Macdonald et al, 1990), published in 1990, provided an objective radiologic assessment of tumor response, based on the product of the maximal cross-sectional enhancing diameters as the primary tumor measure. In the Macdonald Criteria, a significant increase (at least 25%) in the contrast-enhancing lesion is used as a reliable surrogate marker for tumor progression, and its presence mandates a change in therapy. However, increased enhancement can also be induced by a variety of non-tumoral processes such as treatment-related inflammation, seizure activity, postsurgical changes, ischemia, sub-acute radiation effects, and radiation necrosis (Van den Bent et al, 2009).

25 **[0007]** In this context, post-treatment radiographic changes observed within several months of temozolomide-based chemoradiation, have been recently referred to as pseudoprogression. This treatment related effect has implications for patient management and may result in premature discontinuation of effective adjuvant therapy. This limits the validity of a progression free survival end point unless tissue-based confirmation of tumor progression is obtained. It also has significant implications for selecting appropriate patients for participation in clinical trials for recurrent gliomas. Pseudoprogression was widely reported within the last 5 years in glioma patients undergoing standard chemoradiation. These papers demonstrate that 26-58% of the patients suffer early disease progression at first post-concomitant chemoradiation imaging. Within those patients which continued treatment, 28-66% showed radiologic improvement or stabilization and were defined retrospectively as manifesting pseudoprogression.

30 **[0008]** Thus, treatment decisions, as to whether to operate on a patient with radiographic deterioration, continue chemotherapy or change to another non-surgical treatment is a day to day struggle involving interdisciplinary teams of neurosurgeons, neuro-oncologists and neuro-radiologists who are often unable to reach a unanimous interpretation of the patient status.

[0009] For glioblastoma patients treated by radiation and TMZ, conventional MRI is unable to provide a reliable distinction between tumor progression and treatment effects (also referred to as pseudoprogression). For glioblastoma patients conventional MRI is unable to reliably depict the tumor or pseudoprogression after treatment with Bevacizumab.

35 **[0010]** MRS can distinguish residual or recurrent tumors from pure treatment-related necrosis, but not from mixed necrosis and tumor tissue. Diffusion weighted MRI (DWMRI) has also been assessed for differentiating tumor/necrosis after RT, however, the specificity of DWMRI is less than MRS. It has been suggested that combining DWMRI with MRS may improve the differentiation. FDG-PET has been shown to be useful in differentiating necrosis from recurrence, but the reported sensitivity and specificity were again low.

40 **[0011]** A number of MRI techniques have been applied to study microvasculature parameters in this context. The two most commonly used methods are dynamic contrast-enhanced MRI (DCE MRI) and dynamic susceptibility-weighted contrast MRI. DCE MRI measures the changes in T1 relaxation associated with disrupted blood brain barrier following contrast administration using parameters such as fractional blood volume (fBV) and permeability (Kps or Ktrans). DSC MRI uses echo planar sequences with a rapid bolus of gadolinium-based contrast agents to assess changes in T2* within the vasculature and interstitial space. Typical calculated parameters are the relative peak height (rPH), relative cerebral blood volume (rCBV) and the percentage recovery (%REC) or recirculation factor (RF).

55 **[0012]** Parametric maps that are derived from DCE and DSC data have been proposed as noninvasive methods for assessing response to therapy. Radiation necrosis typically shows decreased rCBV, whereas recurrence shows high rCBV. Unfortunately, there was significant overlap between the two groups. More encouraging results were obtained

using delayed T1-weighted MRI (T1-MRI) permeability methods, which image beyond the first pass circulation of contrast, sometimes as long as 10-15 min. using such a delay, one group was able to reliably distinguish between recurrence, radiation necrosis, and a combination of both factors. They found that radiation necrosis and tumor enhance at different rates, enabling significant differentiation between recurrent tumor, radiation necrosis and mixed radiation necrosis and tumor ($p < 0.001$). One group showed that using intra-tumoral and peri-tumoral MRI information it was possible to predict activation of hypoxia and proliferation gene-expression programs, respectively. Furthermore, the intratumoral distribution of gene-expression patterns was found to predict patient outcome.

[0013] DSC was recently applied, demonstrating the feasibility for differentiating pseudoprogression from real tumor progression using ferumoxytol. One group applied DCE to a cohort of 29 patients with gliomas and brain metastasis suspected of treatment-induced necrosis or recurrent/progressive tumor and demonstrated the feasibility of predicting real progression. Another group applied DSC MRI for differentiating tumor progression from radiation necrosis in glioblastoma multiforme (GBM) patients undergoing external beam radiation therapy. Their analysis showed that rPH and rCBV were significantly higher in patients with recurrent GBM than in patients with radiation necrosis while the %REC values were significantly lower.

[0014] Brain metastases are the most common intracranial tumor in adults, occurring in approximately 10% to 30% of adult cancer patients. It is believed that the annual incidence is rising (due to better treatment of systemic disease and improved imaging modalities). The prognosis of patients diagnosed with brain metastases is generally poor.

[0015] Stereotactic radiosurgery (SRS) is a radiotherapy technique which permits the delivery of a single large dose of radiation to the tumor while minimizing irradiation of adjacent normal tissue. It is applied to treat both benign and malignant tumors as well as for vascular lesions and functional disorders. Among the reported complications of SRS is radiation-induced necrosis which, similarly to pseudoprogression, can be difficult to differentiate both clinically and radiologically from recurrent tumor at the treatment site. The incidence of radiation induced necrosis may vary between 5% to 11% according to the volume of the treated lesion and the applied dose (19).

[0016] Tumor progression, inflammation, infection and treatment-induced changes (such as radiotherapy-induced changes) can induce similar changes in enhancement which are impossible to differentiate.

[0017] Previous studies suggest that ~50% of glioblastoma multiforme (GBM, the most frequent and aggressive high grade primary brain tumor) patients and up to ~20% of patients with brain metastases who present radiological deterioration after treatment do not suffer from tumor recurrence but from treatment effects (TEs). These changes, induced by the treatment, often termed pseudoprogression in the case of GBM and radiation necrosis in the case of brain metastases, are depicted as increasing volumes of contrast-enhancing lesions on conventional MRI, mimicking tumor progression. Treatment decision, as whether to operate on a patient with radiographic deterioration, continue current treatment/follow-up or change to another non-surgical treatment is a daily struggle involving interdisciplinary teams of neurosurgeons, neuro-oncologists and neuro-radiologists which are often unable to reach unanimous interpretation of the patient's status. Therefore, reliable distinction between these conditions is essential for appropriate patient management.

[0018] The fact that increases in enhancing lesion volume in 20-30% of patients is due to treatment effects rather than tumor progression, prevents appropriate treatment in ~50% of patients with brain tumors. Some of these patients undergo unnecessary surgeries or treatment changes when continuation of the current treatment should be the correct choice, while others do not receive the necessary surgery/treatment on time. In both cases, the wrong choice of treatment significantly hampers the patient's quality of life and survival. For patients suffering from these devastating diseases, with survival measured in months, taking the right decision at the right time is a matter of life and death.

[0019] Conventional MRI is currently unable to provide reliable distinction between tumor progression and treatment effects such as pseudoprogression and radiation necrosis. MR spectroscopy (MRS) can distinguish residual or recurrent tumors from pure treatment-related necrosis, but not from mixed necrosis and tumor tissue. Diffusion weighted MRI (DWMRI) and diffusion-tensor MRI have also been assessed for differentiating tumor/necrosis after RT, however, the specificity of DWMRI is less than MRS. FDG-PET has been shown to be useful in differentiating RN from recurrence, but the reported sensitivity/specificity of FDG PET in the brain are low. There is limited, but increasing evidence that PET with amino acid tracers may contribute to the differentiation between treatment effects and recurrence. Whether these techniques will also allow a reliable distinction between pseudoprogression and real progression is yet to be determined.

[0020] The most studied MRI methodology in this context is perfusion-weighted MRI (PWI), applied for assessing microvasculature parameters. The most commonly applied PWI methods are dynamic contrast-enhanced MRI (DCE MRI) and dynamic susceptibility-weighted contrast MRI (DSC MRI). Parametric maps derived from DCE and DSC have been proposed for assessing response to therapy. Treatment induced changes typically show decreased relative cerebral blood volume (rCBV), whereas recurrence shows high rCBV. Still, most of these studies show some degree of overlap between the two disease entities. In addition, using fast acquisition techniques has the disadvantages of low spatial resolution and high sensitivity to susceptibility artifacts. Due to these limitations, in many cases the data is inconclusive and significant results are mostly obtained by averaging over the entire enhancing lesion while important information

regarding the location and shape of small active tumor regions may be limited. This effect stands out especially in the case of GBM, where pseudoprogression hardly ever describes a status with no residual tumor (unlike the case of brain metastases and RN where complete tumor resolution is more likely to occur), as we know that the vast majority of all GBM patients, including those experiencing pseudoprogression, eventually recur.

[0021] Zach et al (PLOS One 2012) have described a way to differentiate tumor progression from treatment-induced effects by subtraction maps calculated from data acquired at 2 and 75 min post contrast administration.

SUMMARY OF THE INVENTION

[0022] The object of the present invention is achieved with a system and method according to the independent claims.

[0023] According to an aspect of some embodiments of the present invention there is provided apparatus for operating MRI, comprising: a control for operating an MRI scanner to carry out an MRI scan of an organ of a subject; an input for receiving first and second MRI scans respectively at the beginning and end of a predetermined time interval post contrast administration; a subtraction map former for forming a subtraction map from the first and the second MRI scans by analyzing the scans to distinguish between two primary populations, a slow population, in which contrast clearance from the tissue is slower than contrast accumulation, and a fast population in which clearance is faster than accumulation; and an output to provide an indication of distribution of the two primary populations, wherein the control is configured to carry out the first scan at least five minutes and no more than twenty minutes post contrast administration and to carry out the second scan such that the predetermined time period is at least twenty minutes.

[0024] According to an aspect of some embodiments of the present invention there is provided apparatus for operating MRI, comprising: an MRI Scanner configured for performing a 3D MRI scan; an input for receiving first and second MRI scans of an organ of a subject respectively at the beginning and end of a predetermined time interval post contrast administration from the MRI scanner; a subtraction map former for forming a subtraction map from the first and the second MRI scans by analyzing the scans to distinguish between two primary populations, a slow population, in which contrast clearance from the tissue is slower than contrast accumulation, and a fast population in which clearance is faster than accumulation; and an output to provide an indication of distribution of the two primary populations, wherein the control is configured to carry out the first scan and the second scan such that the predetermined time period is at least twenty minutes.

[0025] According to some embodiments of the invention the subtraction map former comprises an intensity map constructor for constructing, for each magnetic resonance image, an intensity map, wherein the subtraction map describes variations in concentration of the contrast agent in the organ by detecting dissimilarities among a pair of intensity maps.

[0026] According to some embodiments of the invention the predetermined time period is any one of the group consisting of: more than twenty minutes, more than thirty minutes, more than forty minutes, more than fifty minutes, more than sixty minutes, more than seventy minutes, more than eighty minutes, more than ninety minutes, more than a hundred minutes, seventy minutes, seventy five minutes and ninety minutes.

[0027] According to some embodiments of the invention the subtraction map former is configured for assigning a representative intensity value for a selected ROI in each magnetic resonance image and determining a time-dependence of the representative intensity value.

[0028] According to some embodiments of the invention the subtraction map former is configured for differentiating between morphologically active tumor represented by the fast population, and a non-tumoral tissue represented by the slow population.

[0029] According to some embodiments of the invention the input receives from the MRI scanner at least one additional MRI scans before the first MRI scan, the MRI scans being acquired post contrast administration, and wherein the subtraction map former is configured for forming a first subtraction map using the additional MRI scan and the second MRI scan, and a second subtraction map using the first MRI scan and the second MRI scan.

[0030] According to some embodiments of the invention the subtraction map former is configured for forming a third map having regions corresponding to the slow population as obtained from the first map, and regions corresponding to the fast population as obtained from the second map.

[0031] According to some embodiments of the invention the slow population corresponds to an abnormal but non-tumoral tissue region.

[0032] According to some embodiments of the invention the abnormal but non-tumoral tissue region corresponds to a treatment effect.

[0033] According to some embodiments of the invention the abnormal but non-tumoral tissue region corresponds to an inflammation.

[0034] According to some embodiments of the invention the abnormal but non-tumoral tissue region corresponds to BBB disruption.

[0035] According to some embodiments of the invention the apparatus is configured to carry out image pre-processing.

[0036] According to some embodiments of the invention the preprocessing comprises registration.

[0037] According to some embodiments of the invention the preprocessing comprises correction for intensity variations.

[0038] According to some embodiments of the invention the apparatus comprises a registration unit for carrying out registration between corresponding MRI images.

[0039] According to some embodiments of the invention the registration comprises a rigid body registration.

5 **[0040]** According to some embodiments of the invention the registration comprises an elastic registration to allow for head movements and resulting distortions between respective scans.

[0041] According to some embodiments of the invention the elastic registration comprises dividing each slice of a respective scan into a grid of volumes, and allowing each volume to move freely in three dimensions until a sum of the absolute values of the intensity difference between the two time points reaches a minimum.

10 **[0042]** According to some embodiments of the invention the apparatus comprises a smoothing and interpolation unit for smoothing a 3 dimensional translation matrix resulting from the registration using circular smearing, and interpolating to obtain translation values per pixel.

[0043] According to some embodiments of the invention the apparatus comprises a data processor configured for estimating a progression time of a tumor, based on initial growth rate in the fast population.

15 **[0044]** According to an aspect of some embodiments of the present invention there is provided a method for analyzing MRI of an organ of a subject, comprising: receiving a first and a second MRI scan at the beginning and end of a predetermined time interval post contrast administration, wherein the time interval begins at least five minutes and no more than ten minutes post contrast injection; forming a subtraction map from the first and the second MRI scans by analyzing the scans to distinguish between two primary populations, a slow population, in which contrast clearance from the tissue is slower than contrast accumulation, and a fast population in which clearance is faster than accumulation; and providing an indication of distribution of the two primary populations, wherein the predetermined time period is at least twenty minutes.

20 **[0045]** According to an aspect of some embodiments of the present invention there is provided a method for analyzing MRI of an organ of a subject, comprising: receiving a first and a second 3D MRI scan at the beginning and end of a predetermined time interval post contrast administration; forming a subtraction map from the first and the second 3D MRI scans by analyzing the scans to distinguish between two primary populations, a slow population, in which contrast clearance from the tissue is slower than contrast accumulation, and a fast population in which clearance is faster than accumulation; and providing an indication of distribution of the two primary populations, wherein the predetermined time period is at least twenty minutes.

25 **[0046]** According to some embodiments of the invention the forming comprises constructing, for each magnetic resonance image, an intensity map, wherein the subtraction map describes variations in concentration of the contrast agent in the organ by detecting dissimilarities among a pair of intensity maps.

[0047] According to some embodiments of the invention the method further comprising using the map to distinguish between residual tumor post-surgery and post-surgical changes.

30 **[0048]** According to some embodiments of the invention the predetermined time period is any one of the group consisting of: more than twenty minutes, more than thirty minutes, more than forty minutes, more than fifty minutes, more than sixty minutes, more than seventy minutes, more than eighty minutes, more than ninety minutes, more than a hundred minutes, seventy minutes, seventy five minutes and ninety minutes.

35 **[0049]** According to an aspect of some embodiments of the present invention there is provided a method comprises receiving at least one additional MRI scans before the first MRI scan, the additional MRI scan being acquired post contrast administration, and wherein the forming the subtraction map comprises forming a first subtraction map using the additional MRI scan and the second MRI scan, and a second subtraction map using the first MRI scan and the second MRI scan.

40 **[0050]** According to some embodiments of the invention the method comprises identifying the slow population using the first map, and for identifying the fast population using the second map.

[0051] According to some embodiments of the invention the method comprises identifying the slow population using the first map but not the second map, and for identifying the fast population using the second map but not the first map.

45 **[0052]** According to some embodiments of the invention the method comprises forming a third map having regions corresponding to the slow population as obtained from the first map, and regions corresponding to the fast population as obtained from the second map.

[0053] According to some embodiments of the invention the method comprises assigning a representative intensity value for each magnetic resonance image and determining a time-dependence of the representative intensity value.

[0054] According to some embodiments of the invention the method comprises generating a graph describing the time-dependence.

50 **[0055]** According to some embodiments of the invention the method comprises determining, from the subtraction map, whether tumour tissue is present, by comparing drainage of the contrast agent from blood vessels with contrast agent take up in the tissue.

[0056] According to some embodiments of the invention the method comprises differentiating between morphologically

active tumor represented by the fast population, and a non-tumoral tissue represented by the slow population.

[0057] According to some embodiments of the invention the method comprises carrying out image preprocessing.

[0058] According to some embodiments of the invention the preprocessing comprising registration.

[0059] According to some embodiments of the invention the preprocessing comprising correction for intensity variations.

[0060] According to some embodiments of the invention the correction for intensity variations comprises calculating, for each MRI image separately, an intensity variation map consisting of large scale intensity variations therein and then subtracting the intensity variation map from the respective image.

[0061] According to some embodiments of the invention the method comprises estimating a progression time of a tumor, based on initial growth rate in the fast population.

[0062] According to some embodiments of the invention the method comprises using the maps for differentiation between tumor progression and radiation necrosis.

[0063] According to some embodiments of the invention the method comprises depiction of tumors in the organ after treatment with chemotherapy and/or radiation-based treatments, for differentiation between tumor progression and pseudoprogression.

[0064] According to an aspect of some embodiments of the present invention there is provided a method for managing tumor treatment in patients, comprising: receiving a first and a second 3D MRI scan at the beginning and end of a predetermined time interval post contrast administration; forming a subtraction map from the first and the second 3D MRI scans by analyzing the scans to distinguish between two primary populations, a slow population, in which contrast clearance from the tissue is slower than contrast accumulation, and a fast population in which clearance is faster than accumulation; and providing an indication of distribution of the two primary populations, wherein the predetermined time period is at least twenty minutes; using the subtraction map and the indication to distinguish between tumor and non-tumor tissue and thereby to provide information for determination of further treatment.

[0065] According to some embodiments of the invention the the subject has a cancer of a type selected from the group consisting of a brain tumor, Ewing sarcoma, a Head and neck tumor, a lung cancer, a colon and rectum cancer, a breast cancer, a prostate cancer, a urinary cancer, a uterine cancer, a bladder cancer, an oral cancer, a pancreatic cancer, a stomach cancer, an ovarian cancer, a liver cancer, a laryngeal cancer, a thyroid cancer, a esophageal cancer, and a testicular cancer.

[0066] According to some embodiments of the invention the organ is selected from the group consisting of brain, colon, prostate, bladder, breast, chest, lung, liver, bones and bone marrow, ovary, kidneys, spleen, thyroid gland, pancreas, head and neck, extremities, skin, lymph nodes, brain, colon, prostate, breast, lung, liver, bones and bone marrow, ovary, pancreas, head and neck, skin, abdomen, eyes, heart, stomach.

[0067] Some embodiments of the present invention are used for depiction of a space occupying lesion (SOL) in the organ after treatment, for differentiation between disease progression and treatment effects.

[0068] According to some embodiments of the invention the SOL comprises at least one object selected from the group consisting of a brain tumor, a primary brain tumor and a brain metastasis.

[0069] According to some embodiments of the invention the SOL comprises at least one object selected from the group consisting of an AVM, a cavernoma, a meningioma, a chordoma and a rare tumor.

[0070] According to some embodiments of the invention the treatment is selected from the group consisting of a chemotherapy, a ionizing radiation therapy, a radiation therapy, a focused radiation therapy, radiosurgery, gamma-knife therapy, intensity modulated therapy, a physical therapy, a thermal therapy, an electrical therapy, an electromagnetic therapy, a radiofrequency therapy, an ultrasound therapy, focused-ultrasound therapy, Transcranial magnetic stimulation, electroporation therapy, laser therapy, cryogenic therapy, anti-angiogenic therapy, immuno-therapy, genetic-based therapy, therapy based on convection-enhanced delivery, and any combination thereof.

[0071] According to some embodiments of the invention the treatment the SOL comprises high-grade glioma, and the treatment comprises chemotherapy, ionizing radiation therapy and a combination of chemotherapy, ionizing radiation therapy.

[0072] According to some embodiments of the invention the treatment the SOL comprises brain metastasis, and the treatment comprises ionizing radiation therapy, including whole brain radiation therapy and focused radiation therapy such as, but not limited to, radiosurgery and gamma knife therapy.

[0073] Some embodiments of the present invention are used for depiction of residual tumor post surgery.

[0074] Some embodiments of the present invention are used for guiding a local treatment of tumor. According to some embodiments of the invention the local treatment is at a spatial resolution of less than 5 mm, more preferably less than 2 mm, more preferably 1 mm or less.

[0075] Some embodiments of the present invention are used for detecting active tumor within bleeding regions.

[0076] Some embodiments of the present invention are used for differentiating malignant transformation from treatment effects in treated low grade tumors.

[0077] Some embodiments of the present invention are used for depiction of tumors in the organ after treatment with

anti-angiogenic treatments and studying the mechanism of action and response patterns of anti-angiogenic drugs.

[0078] Some embodiments of the present invention are used for depiction of tumors in the organ after treatment with radiation-based treatments, for differentiation between tumor progression and radiation necrosis.

[0079] Some embodiments of the present invention are used for depiction of tumors in the organ after treatment with radiation-based treatments, for differentiation between tumor progression and pseudoprogession.

[0080] Some embodiments of the present invention are used for differentiation between progression of brain space occupying lesion (SOL) and treatment effects following focused radiation treatments such as radiosurgery and gamma knife treatments.

[0081] According to some embodiments of the invention the MRI is of a subject diagnosed with GBM, wherein the subtraction map former is configured to identify changes in a volume of the fast population volume, and wherein the output is configured to indicate progression when the increment is above a predetermined threshold.

[0082] Some embodiments of the present invention are used for identifying change in a volume of the fast population volume, wherein a level of increment above a predetermined threshold indicates tumor progression.

[0083] Some embodiments of the present invention are used for differentiating open AVM from at least one of closed AVM and treatment effects.

BRIEF DESCRIPTION OF THE DRAWINGS

[0084] The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in order to provide what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.

[0085] In the drawings:

FIG. 1A is a simplified block diagram showing imaging apparatus for producing subtraction maps according to applicant's earlier application;

FIG. 1B is a simplified block diagram showing the subtraction map former of FIG. 1A in greater detail;

FIGs. 1C and 1F are simplified block diagram showing registration unit and image corrector;

FIGs. 1D and 1E are flowchart diagrams describing a procedure for constructing subtraction maps, according to applicant's earlier application;

FIGs. 2A and 2B show conventional MRI and mapping according to the present embodiments, carried out on either side of a two and a half week interval on the patient of Example 1;

FIGs. 3A-3H show the histology of samples of the patient of Example 1 after surgery;

FIG. 4 is a one month post surgery MRI scan together with mapping according to the present embodiments, indicating success of the surgery and removal of the tumor in the patient of Example 1;

FIGs. 5A-5E are an initial MRI scan and mapping and histology samples for the patient of Example 2;

FIG. 6 is an MRI scan of the patient of Example 7 two weeks post surgery;

FIG. 7 is an MRI scan and mapping according to the present embodiments, of the patient of Example 2 four weeks post surgery;

FIG. 8 shows MRI scans and mapping of the patient of Example 3 at successive time intervals;

FIGs. 9A-9F illustrate two examples in which mappings according to the present embodiments contrast tumor progression effectively against pseudo-progression;

FIG. 10 illustrates MRI scans and mapping according to the present embodiments of the breast cancer patient of example 4 before and after surgery;

FIG. 11 illustrates histology for the patient in FIG. 10;

FIG. 12 illustrates MRI scans and mapping according to the present embodiments for melanoma brain metastasis and Example 6;

FIG. 13 illustrates an MRI scan and mapping of head and neck cancer according to example 7;

FIG. 14 shows two-dimensional and three-dimensional MRI scans and mapping according to the present embodiments of the patient of example 8 and showing three brain metastases of lung cancer;

FIG. 15 illustrates 2D MRI scanning and maps acquired 1 months and three months after a second resection in the tumor patient of example 9 indicating that most of the tumor has been removed 1 month after the surgery but recurrence was detected 3 months post surgery;

FIG. 16 shows 2D conventional MRI and mapping left, and 3D conventional and mapping right of the same patient as in FIG. 15, with the 3D mapping clearly showing that the tumor has recurred;

FIG. 17 illustrates 2D and 3D conventional MRI and mappings according to the present embodiments of the patient of Example 10, with a brain metastasis of ovarian cancer, in which the overall tumor volume seen in the two maps is similar;

FIGs. 18A-I show examples of application of the technique according to some embodiments of the present invention to patients with AVM;

FIG. 19 show examples of application of the technique according to some embodiments of the present invention to a child with an anaplastic chordoma;

FIGs. 20A and 20B show examples of application of the technique according to some embodiments of the present invention to a patient recruited after stereotactic radiosurgery of a chordoma with suspected radiation necrosis;

FIGs. 21A and 21B show examples of application of the technique according to some embodiments of the present invention to a patient after stereotactic surgery treatment of anaplastic meningioma;

FIGs. 22A-D show examples of application of the technique according to some embodiments of the present invention to a patient previously diagnosed with a low grade non-enhancing glioma in the brain stem and spine;

FIGs. 23A and 23B show examples of application of the technique according to some embodiments of the present invention to a patient after surgical removal of a hypofisal adenoma;

FIGs. 24A and 24B show examples of application of the technique according to some embodiments of the present invention to a patient with petroclival meningioma after stereotactic radiosurgery (SRS);

FIGs. 25A-B show examples of application of the technique according to some embodiments of the present invention to rats with CNS1 glioma;

FIG. 26A-D show examples of application of the technique according to some embodiments of the present invention to dogs with spontaneous glioma;

FIG. 27A-B show examples of application of the technique according to some embodiments of the present invention to mice with U87 (human) glioma;

FIGs. 28A and 28B show examples of application of the technique according to some embodiments of the present invention to a patient having malignant melanoma diagnosed with a bleeding lesion in the brain;

FIGs. 29A and 29B show examples of application of the technique according to some embodiments of the present invention to a patient cerebellar metastasis of breast cancer after stereotactic radiosurgery;

FIGs. 30A and 30B show examples of application of the technique according to some embodiments of the present invention to a patient with GBM after 2 resections and treatment with chemoradiation; and

FIG. 31 shows estimated signal intensity (in arbitrary units) as a function of the time after injection of contrast agent for signals corresponding to two tumors, and for a signal corresponding to a treatment effect.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0086] The present invention, in some embodiments thereof, relates to method and apparatus for producing magnetic resonance (MR)-based maps and, more particularly, but not exclusively to using such maps to identify and study tumors.

[0087] The present embodiments can be applied to any MR image of any part of the body, including, without limitation, brain, colon, prostate, bladder, breast, chest, lung, liver, bones and bone marrow, ovary, kidneys, spleen, thyroid gland, pancreas, head and neck, extremities, skin, lymph nodes, brain, colon, prostate, breast, lung, liver, bones and bone marrow, ovary, pancreas, head and neck, skin, abdomen, eyes, heart, stomach. The present embodiments are particularly useful for analyzing tumors or tissues which are suspected as tumors.

[0088] The present embodiments provide an MRI-based methodology providing high resolution maps with clear differentiation between tumor and non-tumoral tissues in patients having one or more tumors, unattainable by current imaging methods. This enablement system is based on delayed contrast extravasation MRI.

[0089] The present embodiments are useful also the analysis of tissues in subjects having a cancer or subjects being suspected as having a cancer. Typically, the cancer is of a solid tumor cancer. Representative examples of solid tumor cancers for which the technique of the present embodiments is applicable, include, without limitation, brain tumors, Ewing sarcoma, Head and neck tumors, lung cancer, colon and rectum cancer, breast cancer, prostate cancer, urinary cancer, uterine cancer, bladder cancer, oral cancer, pancreatic cancer, stomach cancer, ovarian cancer, liver cancer, laryngeal cancer, thyroid cancer, esophageal cancer, lymphomas, leukemias, and testicular cancer. The present embodiments are useful for the analysis of tissues in subjects having primary tumors, secondary tumors, metastatic tumors, intra-cranial tumors and extra-cranial.

[0090] While the embodiments below are described with a particular emphasis to brain tumors, it is to be understood that more detailed reference to brain tumors is not to be interpreted as limiting.

[0091] In various exemplary embodiments of the invention two sets of MR images are acquired. A first set of MR images is taken such that the MR scan begins t1 minutes after injection of contrast agent, and a second set of MR images is taken such that the MR scan begins t2 minutes after injection of contrast agent, wherein t1 is at least 2 and preferably less than 20, and the difference t2-t1 is at least 20, optionally and preferably at least 60, optionally and

preferably less than 120. For example, t1 can be from about 3 to about 20, or from about 3 to about 15, or from about 3 to about 10, or from about 4 to about 10, or from about 5 to about 10, or from about 3 to about 7, e.g., about 3 or about 4 or about 5 or about 6 or about 7 or about 8 or about 9 or about 10; and t2 can be from about 60 to about 120, or from about 60 to about 105, or from about 65 to about 85, or from about 70 to about 80, e.g., about 70 or about 75 or about 80. Each measurement typically requires from about 2 to about 6 min of MR scanning, and the subject can be allowed to exit the MR scanner between the two time points.

[0092] The MR images are then used to calculate maps clearly depicting tumoral regions in one color (for example, blue) and non-tumor regions (including treatment effects, inflammatory-related pathological and, in case of brain MRI, other types of non-tumoral BBB disruption) in a different color (for example, red), based on their contrast accumulation or clearance patterns. The images can be acquired on any clinical MR scanner using the conventional type/dose of contrast agents and the resulting maps provide high resolution depiction of the tissues with an easy to interpret color code. Data analysis is model-independent and optionally and preferably comprises image pre-processing (for overcoming acquisition-related artifacts) and subtraction of the early images (acquired t1 minutes post contrast injection) from the late images (acquired t2 minutes post contrast injection).

[0093] A map can be constructed for the same subject more than once, wherein each such map is constructed by subtracting an MR scan taken t1 minutes after injection of contrast agent from an MR scan taken t2 minutes after injection of contrast agent. For example, a first map can be constructed before a treatment and a second map can be constructed after a treatment, so as to assess the effect of the treatment.

[0094] The assessment of the effect of the treatment can include, but is not limited to, assessing the responsiveness of the tumor to the treatment (e.g., whether the size of the tumor has changed), distinguishing between an active tumor and a tissue region which is not a tumor but which is abnormal, for example, due to treatment effects, assessing tumor progression or lack thereof, assessing tumor pseudo-progression, assessing whether there is residual tumor after treatment. The maps of the present embodiments can also be used to detect tumors within bleeding regions.

[0095] The maps can be used to assess the effect of any therapy employed for the purpose of affecting, decreasing or eliminating a tumor or any other pathology, including, without limitation, arteriovenous malformation (AVM), such as, but not limited to, pelvic AVM, kidney AVM, liver AVM, spinal AVM, brain AVM, and pulmonary AVM. For example, the therapy can comprise chemotherapy, such as a drug, and/or a radiation-based therapy. The therapy can include a second therapeutic agent, such as a gene-specific or non-gene-specific therapeutic agent, such as an siRNA, antisense RNA, triple helix RNA, ribozyme, antibody, or small molecule inhibitor. The therapy can comprise at least one of chemotherapy, a ionizing radiation therapy, a radiation therapy, a focused radiation therapy, radiosurgery, gamma-knife therapy, intensity modulated therapy, a physical therapy, a thermal therapy, an electrical therapy, an electromagnetic therapy, a radiofrequency therapy, an ultrasound therapy, focused-ultrasound therapy, Transcranial magnetic stimulation, electroporation therapy, laser therapy, cryogenic therapy, anti-angiogenic therapy, immuno-therapy, genetic-based therapy, therapy based on convection-enhanced delivery. The therapy can comprise a proliferation based therapy. Non-limiting examples of proliferation based therapies include an alkylating agent, a nitrosourea, an antimetabolite, an anthracyclin, a topoisomerase II inhibitor, spindle poison, and a mitotic inhibitor. Any combination of two or more of the above therapies with or without an additional therapy other than any of the above therapies is also contemplated.

[0096] When more than one map is constructed for the same subject, for example for the purpose of assessing response to treatment over a period of several weeks, months or years, the time t1 is preferably approximately the same (with a tolerance of up to 2 minutes, more preferably up to 1 minute, more preferably up to 30 seconds) for all the maps that are constructed for the subject. The time t2 can be the same or different as desired but preferably at least 60 minutes after t1. The differences between the t2 times among maps of the same subject can be from 0 minutes to 50 minutes. For example, before treatment t1 can equal 5 minutes and t2 can equal 60 minutes, and after treatment t1 can equal 5 minutes and t2 can be at least 70 minutes or at least 80 minutes or at least 110 minutes.

[0097] A map can optionally and preferably be constructed for the same subject, for the same MRI exam, more than once, using three or more MRI series. For example, two or more values of the time t1 can be employed, wherein a separate map is constructed for each value of the time t1. As a representative example, a series of MR images can be taken such that the scan begins t1(0) minutes after injection of contrast agent, another series of MR images can be taken such that the scan begins t1(1) minutes after the injection of the contrast agent, and an additional series of MR images can be taken such that the scan begins t2 minutes after injection of contrast agent, where t1(0) is less than t1(1), and t1(1) is less or equals t1 as defined above, for example t1(0) can be less than 3, e.g., 2, t1(1) can be from about 3 to about 20, e.g., 5, and t2 can be at least 60 but less than 120. From these three series, two maps can be constructed. A first map can be constructed by subtracting the series corresponding to t1(0) from the series corresponding to t2, and a second map can be constructed by subtracting the series corresponding to t1(1) from the series corresponding to t2. It was unexpectedly found by the present inventors that the first map is more accurate for determining locations of non-tumoral regions and the second map is more accurate for determining locations of tumoral regions. Optionally, a third map is also constructed by combining the information of both maps. Preferably the non-tumoral regions of the third map are extracted from the first map and the tumoral regions of the third map are extracted from the second map.

[0098] In some embodiments of the present invention the subtraction maps are blood vessel function maps.

[0099] The present inventors validated the obtained maps histologically by comparing the pre-surgical maps with histological samples acquired from 51 lesions obtained from 47 patients with primary and metastatic brain tumors (first 20 patients listed in Zach et al, PLOS One 2012). In most cases regions marked on the maps as tumoral regions were determined to consist of morphologically active tumor and regions marked on the maps as non-tumor regions were histologically found to be non-tumor abnormal tissues. Taking into account all histological samples the sensitivity was found to reach 99% and the positive predictive value 95%. The maps optionally and preferably may thus be used for clinical decisions.

[0100] Preferably, a T1-weighted MRI pulse sequence is employed. In some embodiments of the invention, the MR scan employs a pulse sequence of a type known as 3D MRI. A representative example of a 3D MRI technique suitable for the present embodiments include, without limitation, fast spoiled prepared gradient echo.

[0101] The advantage of using 3D MRI is that higher resolution can be achieved (important both for correct interpretation of the patient status as well as for high precision treatment planning) and the 3D information allows the physician to observe the pathology from any angle. In some embodiments a 1 mm³ resolution is used, compared to 5 mm slice resolution in 2D MRI.

[0102] Successfully using t1 which is about 5 minutes or more, but preferably not more than 10 minutes was a surprise. Previous work described herein uses t1=2 minutes, since the time is measured from the administration of contrast agent, and given that the signal rise in the blood vessels is fast, the working assumption would be to take the first image as soon as possible.

[0103] When studying the dependence of the signal rise on the time post contrast injection for different regions in the pathological areas, it was unexpectedly found that, on average, tumor tissues reach peak signal intensity at different and longer times than normal blood vessels. Without wishing to be bound to any particular theory, the present inventors provides the following explanation for the discovered surprising effect.

[0104] Leakiness of the blood vessels causes ongoing accumulation of contrast agent in the tissue. Therefore, the signal intensity of tumor tissues for t1 which is, for example, 10 minutes may reach higher values than that of 2 min, resulting in a larger absolute difference between t2 and t1, thus increased sensitivity to tumoral tissues. On the other hand, the sensitivity to treatment effects may be reduced since the signal of these types of tissues also rises between 2 and 10 minutes post contrast injection, thus reducing the absolute difference between t2 and t1.

[0105] FIG. 31 shows an estimated signal intensity (in arbitrary units) as a function of the time after injection of contrast agent for signals corresponding to two tumors (referred to in FIG. 31 as tumor 1 and tumor 2), and for a signal corresponding to a treatment effect. As shown, the treatment effects signal intensity keeps rising throughout the 60 minutes post contrast, the signal intensity of tumor 1 increases fast and then decreases fast, and the signal intensity of tumor 2 increases fast, but slower than tumor 1. In this example, for t1=2 min, the difference in signal intensity of the treatment effects between the two time points is 8.5, of tumor 1 is 8 and of tumor 2 is 5. For t1=5 min, the difference in signal intensity of the treatment effects between the two time points is 7 (thus decreased sensitivity than for t1=2 min), of tumor 1 is 7.7 (similar that of t1=2 min) and of tumor 2 is 8 (increased sensitivity than for t1=2min).

[0106] It was found by the Inventors of the present invention that, as discussed above, by acquiring late MRI data up to twenty or more minutes, up to 60 or more minutes, or up to 75 min post contrast administration, or even up to 90 minutes or more, or even up to 100 minutes or more, or even up to 120 minutes or more, can add unique information regarding the late contrast clearance or accumulation component. Calculated maps of these unique enhancement and clearance characteristics were found to provide a clear distinction between tumor and non-tumoral tissues with high resolution and high sensitivity to subtle blood brain barrier disruption.

[0107] The current standard of care for newly diagnosed glioblastoma multiforme (GBM) is resection, when possible, followed by radiotherapy with concomitant and adjuvant temozolomide. Pseudoprogression is a radiographic term referring to early increase in enhancement seen post treatment with improvement/stability after a couple of months. Conventional MRI is currently unable to differentiate between tumor progression and pseudoprogression. Since the treatment depends greatly on this question, reliable distinction between the two conditions is crucial.

[0108] The methodology is based on delayed contrast extravasation MRI for calculating subtraction maps depicting unique characteristics with high resolution and high sensitivity to subtle blood brain barrier disruption. These maps provide clear depiction of tumor and non-tumoral components of enhancing GBM lesions.

[0109] Significant correlation found between the maps and conventional contrast-enhanced MRI suggest that on average 50% of the enhancing lesion on conventional MRI does not represent morphological active tumor. The application for prediction of response to therapy was demonstrated by significant correlations between initial vessel function values and later tumor volumes on conventional MRI. Only one patient within this cohort showed no blue component in any of his images. This patient is currently progression free for three years after chemoradiation.

[0110] Subtraction maps based on the above-mentioned delays enable high resolution differentiation between tumor and non tumoral tissues. The information provided allows for appropriate patient management, both in deciding whether to operate on a patient with radiologic deterioration, continue chemoradiation or change to a second line non-surgical

treatment. The present maps may also be applied for planning resection in the most efficient and safe manner and for early prediction of response to therapy, thus enabling selection of patients susceptible to benefit from the treatment.

5 [0111] The application of the maps of the present embodiments for routine patient monitoring, exposes new patterns of response, even to known therapies (moreover for new therapies), since the maps allow depiction of the real tumor burden and thus changes in the tumor in response to therapy. For example, the term pseudoprogression was realized in the last few years and in various papers authors refer to pseudoprogression as a separate condition of pure treatment effects. In a cohort of 39 patients with primary brain tumors recruited post chemoradiation to a study performed according to some embodiments of the present invention no a patient with pure treatment effects has been observed. The present inventors have thus concluded that such conditions are rare. Two of the patients were recruited with no residual tumor post surgery (no blue component in the maps) and they are currently disease free and under follow-up nearly 1 and 3 years post chemoradiation. Either than those, all the other 37 patients, even those showing significant treatment effects in the maps, showed some component of active tumor throughout their follow-ups. The ability to easily differentiate tumor from non-tumoral tissues enabled the technique of the present embodiments to determine the pattern of pseudoprogression as significant increase in the non-tumoral component (e.g., red region on the map), with a stable, (or slower increase or decrease of the), tumor component (e.g., blue region on the map). Using the maps the present inventors found that progression is characterized by increasing blue/tumor volumes (while lesion volume on contrast-enhanced T1-MRI does not necessarily change) and response to treatment is characterized by stable or decreasing blue/tumor volumes. These clear observations were not attainable without the high resolution reliable differentiation between tumor and non-tumoral tissues provided by the maps. In the case of brain metastases, we have learned that even when a component of morphologically active tumor exists in the maps, it can be stable for long periods (up to 9 months in our cohort of 53 recruited patients) enabling postponing resection till increase in the blue/tumor volume is noticed.

15 [0112] Due to improved treatment protocols and extended survival radiation-induced neuro-toxicity of patients with tumors undergoing radiation-based therapies has become a major concern and efforts to minimize unnecessary exposure of surrounding normal tissue without compromising treatment efficacy are of increasing interest. The ability of our maps to depict morphologically active tumor regions with high resolution may thus be applied for accurate radiation treatment planning by localizing the treatment to the tumor/blue regions in our maps thus enabling efficient treatments with minimum toxicity to normal surrounding tissues.

20 [0113] The maps of the present embodiments can be used for guiding a local treatment of tumor. The local treatment is optionally and preferably at a spatial resolution of less than 5 mm, more preferably less than 2 mm, more preferably 1 mm or less. The spatial resolution of the treatment refers to the accuracy of the treatment tool, and not necessarily to the size of the treated region. In a representative example, the maps of the present embodiments are loaded onto the navigation systems in the operating room for accurate targeting of invasive procedures such as guided biopsies, surgeries and implantation of treatment devices. The maps of the present embodiments can also be loaded onto radiation-based treatment planning workstation for accurate targeting of radiation-based treatments such as, but not limited to, intensity modulated radiotherapy, radiosurgery and gamma-knife treatments.

25 [0114] An increasing concern regarding radiation injury, hampers the option of applying high dose radiation treatment to the surgery site after resection of metastases. A further application of the maps optionally and preferably can be to differentiate residual tumor from post surgery changes, thus allowing selecting patients who will benefit from post surgery radiation and use the maps for targeting the treatment only to regions of residual tumor.

30 [0115] The present embodiments are also useful also for improving patient management, for example, by differentiating tumor progression from treatment effects, of any type of solid tumor.

35 [0116] The principles and operation of an apparatus and method according to the present invention may be better understood with reference to the drawings and accompanying description.

40 [0117] Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.

45 [0118] Reference is now made to Fig. 1A which illustrates apparatus 10 for analyzing tissue, such as, but not limited to, brain tissue, comprising an input 12 for receiving a first and a second MRI series at the beginning and end of a predetermined time interval, and a subtraction map former 14. The subtraction map former forms a subtraction map from the two MRI series by analyzing the series to distinguish between two primary populations, a slow population, in which contrast clearance from the tissue is slower than contrast accumulation, and a fast population in which clearance is faster than accumulation. An output 16 provides an indication of distribution of the two primary populations. In the present embodiments, the time period between the two series is at least twenty minutes. The time period may additionally exceed thirty minutes, or even forty minutes, or fifty minutes, or sixty minutes, or seventy minutes, or eighty minutes, or ninety minutes, or a hundred minutes. Specifically, time periods used may be seventy minutes, or seventy five minutes or ninety minutes.

[0119] Reference is now made to Fig. 1B which shows the subtraction map former of Fig. 1A in greater detail. The subtraction map former includes an intensity map constructor 20 for constructing, for each magnetic resonance image, an intensity map. A subtraction map constructor 22 constructs a subtraction map describing variations in concentration of the contrast agent in the tissue under analysis by detecting dissimilarities among a pair of intensity maps.

[0120] The subtraction map former 14 may assign a representative intensity value for each magnetic resonance image and determining a time-dependence of the representative intensity value.

[0121] The subtraction map former may generate a graph describing the time-dependence.

[0122] The input 12 may typically use high resolution 2D or 3D T1-weighted MR images (T1-MRIs).

[0123] The subtraction map former may use the subtraction map to assess whether tumor tissue is present or whether what appears to be tumor tissue is mere treatment effect, by comparing drainage of the contrast agent versus contrast agent take up.

[0124] The image may be pre-processed at preprocessor 24, prior to subtraction. Preprocessor 24 can include a circuit and computer readable medium storing instructions to be carried by the circuit for preprocessing the image. The preprocessing may involve at least one of:

- a) correction for intensity variations; and
- b) image registration.

[0125] Correction for intensity variations may comprise calculating, for each MR image separately, an intensity variation map consisting of large scale intensity variations therein and then subtracting the intensity variation map from the respective image.

[0126] A registration unit 26 carries out registration between corresponding MR images. Registration unit 26, can be, for example, a dedicated circuitry. Registration may comprise a rigid registration or alternatively an elastic registration, to allow for head movements between the two series.

[0127] Elastic registration may comprise dividing each slice of a respective series into to a grid of volumes, and allowing each volume to move freely in three dimensions until a sum of the absolute values of the intensity difference between the two time points reaches a minimum. A three-dimensional translation matrix is generated to match between the two images.

[0128] Figures 1C and 1F are simplified block diagram showing registration unit 26 and image corrector 42 in greater detail. Preprocessor 24 optionally and preferably comprises an image corrector 42 which performs intensity correction on each image of the MR images. This can be done by calculating an intensity variation map consisting of the large scale intensity variations. In various exemplary embodiments of the invention the map is then subtracted from the original image resulting in a flattened image.

[0129] The flattened image is transmitted from image corrector 42 to registration unit 26. In some embodiments, preprocessor 24 is configured to apply the intensity variation correction to the registered images. In these embodiments image corrector 42 receives the images from registration unit 26, as schematically illustrated in FIG. 1F.

[0130] Registration unit 26 optionally and preferably comprises a rigid body registration unit or circuitry 44 and a local or elastic registration unit or circuitry 46.

[0131] Rigid body registration unit or circuitry 44 is preferably configured to apply a rigid body registration to the second MRI series in order to register it to the first MRI series. The rigid body registration can include, for example, a 6 parameter (rigid body) spatial transformation. The registration can optionally and preferably include execution of least square procedure. Local or elastic registration unit or circuitry 46 is preferably configured to apply elastic registration in order to register the second MRI series to the first MRI series to correct for distortions induced in the MRIs by the organ movements.

[0132] The registration optionally and preferably comprises statistical parametric mapping. Following is a preferred process for performing the registration according to some embodiments of the present invention. The process performs a global registration applied to a region-of-interest in the image. For example, when the MR images are brain MR images, a region-of-interest which is the brain can be defined, and the global registration can be a whole brain registration.

[0133] The process can optionally and preferably perform a procedure for increasing the spatial precision of the global registration. Preferably, a segmentation procedure is employed. Suitable segmentation procedure includes, without limitation, voxel-based morphometric procedure available within the MATLAB® software (The MathWorks, Inc. Natick, MA, U.S.A). A decreasing kernel width can be employed based on the segmentation. The decreasing kernel can optionally and preferably be of the type "Full Width Half Max" (FWHM). When the image includes a brain MRI, a decreasing kernel width with cerebral spinal fluid (CSF) weighting can be employed.

[0134] In various exemplary embodiments of the invention a local registration is applied following the global registration. The local registration is optionally and preferably applied to a sliding slab taken along a slice plane of the MRI. For example, the main MRI slice plane can be used. The size of the sliding slab can be fixed to a predetermined value. Alternatively a sliding slab having a varying size can be employed. A typical size of a sliding slab according to some

embodiments of the present invention is from about 0.5 cm to about 2 cm, e.g., about 1 cm. Such sizes can be used as fixed sizes for a fixed size sliding slab or as initial or average sizes for a varying size sliding slab. In some embodiments of the present invention the process performs a procedure for increasing the spatial precision of the local registration. This procedure can be similar to the procedure described above, except that it is applied to the sliding slab instead of the whole region-of-interest.

[0135] A smoothing and interpolation unit 28 may be located after the registration unit. Smoothing and interpolation unit 28 can be, for example, a dedicated circuitry. The three-dimensional translation matrix resulting from the elastic registration may be smoothed using circular smearing, and then interpolated to obtain translation values per pixel.

[0136] The intensity variation correction performed by image corrector 42 may optionally and preferably comprise radiofrequency (RF) inhomogeneity correction. The RF inhomogeneity correction optionally and preferably sets the mean signal intensity of a region-of-interest (e.g., the brain, for brain MRI) within both registered images to the same value. The RF inhomogeneity correction optionally and preferably comprises three-dimensional filtering applied to each of the registered images in order to obtain smoothed images that can be used for normalizing the non-corrected data. In some embodiments of the present invention, pixels or voxels located outside a region-of-interest of the image (e.g., the brain, for brain MRI) are assigned with synthetic intensity values. For example, these pixels or voxels can be assigned with the mean signal intensity of the region-of-interest before filtering.

[0137] The three-dimensional filtering can be of any type. Representative examples of filters suitable for the present embodiment include, without limitation, Gaussian filters, convolution filters, median filters, separable filters and 'non-separable filters. Typically, Gaussian filtering is employed.

[0138] In some embodiments of the present invention the processor applies a dynamic normalization to the images, preferably, once registered, more preferably once registered and corrected. The dynamic normalization defines the dynamic of the differentiating properties (e.g., colors) displayed by the map. The dynamic normalization optionally and preferably employs a procedure that automatically identifies pixels or voxels that are within non-vessel regions in the image and pixels or voxels within vessel regions in the image. The non-vessel regions can include any region in which no blood vessel has been identified. For example, for a brain MRI, a representative example of a non-vessel region is a region identified as white matter.

[0139] Once the regions are identified, a reference level and a strongest signal decrease (due to contrast clearance between time t_1 and time t_2) are determined. These values are then defined as a subtraction map reference value and a subtraction map negative span, respectively. The subtraction map negative span represents the lowest negative value within the map. A similar procedure can be employed to define a subtraction map positive span, which represents highest positive value within the map. The subtraction map reference value, the subtraction map negative span and the subtraction map positive span are then used to define the differentiating properties (e.g., colors) displayed by the map. For example, regions on the map for which the subtraction results in a negative value can be displayed in different color range than regions on the map for which the subtraction results in a positive value.

[0140] In use, an initial enhancing lesion portion may be determined from the first series, which would typically be made two to ten minutes after contrast injection, as further detailed hereinabove. A threshold is optionally and preferably determined from intensity distribution histograms of the enhancing lesion and surrounding regions and is applied to define narrower region-of-interests (ROIs) that include only enhancing portions of the lesion. The narrower ROIs are thus defined over an entire enhancing region in each slice.

[0141] A lesion volume unit 30 may count a number of pixels in the enhancing portions of the ROIs and to multiply by a volume represented by a single pixel to provide a resulting volume as a parameter for assessment of tumor response. The tumor volume unit can be, for example, a dedicated circuitry.

[0142] In various exemplary embodiments of the invention the enhancing volume is calculated from the first series, acquired at time t_1 . Within this ROI, a count of the pixels or voxels that correspond to tumoral regions (e.g., blue voxels) can be obtained and their sum can optionally and preferably be defined as representing the tumor volume. Thus, the enhancing volume can consist of both blue and red pixels or voxels. The blue pixels or voxels are optionally and preferably counted and are used for calculating the tumor volume while the red pixels or voxels are optionally and preferably counted and used for calculating the volume of treatment effects.

[0143] Figures 1D and 1E are flowchart diagram describing a procedure for constructing subtraction maps, according to some embodiments of the present invention.

[0144] It is to be understood that, unless otherwise defined, the operations described hereinbelow can be executed either contemporaneously or sequentially in many combinations or orders of execution. Specifically, the ordering of the flowchart diagrams is not to be considered as limiting. For example, two or more operations, appearing in the following description or in the flowchart diagrams in a particular order, can be executed in a different order (e.g., a reverse order) or substantially contemporaneously. Additionally, several operations described below are optional and may not be executed.

[0145] Referring to Figure 1D, at 51, 2 series of MR images are obtained. A first series can be acquired soon after contrast administration and a second series can be acquired after a predetermined time period as further detailed

hereinabove.

[0146] At 52, the tow series are preprocessed, for example, by applying registration and/or intensity correction as further detailed hereinabove. At 53, the pre-processed first series is subtracted from the pre-processed second series. At 54, the volumes of the various populations (such as, but not limited to, the slow and fast populations) that appear in the maps are calculated.

[0147] Optionally and preferably the subtraction maps are used during a longitudinal follow-up of a patient. In these embodiments a time dependence is evaluated (55) throughout the follow-up of the patient. For example, parameter calculated from the maps at different follow-up time points of a patient can be used for predicting and/or monitoring the response of the patient for treatment. For example, the change in blue volume between the first 2 follow-up time points of a patient can be used for prediction of time-to-progression.

[0148] In some embodiments of the present invention more than 2 series of MR images are obtained. A representative example of these embodiments is illustrated in Figure 1E. Thus, at 61 N series of MR images are obtained. The first series is preferably acquired soon after contrast administration, as further detailed hereinabove. The additional N-1 are preferably acquired at various time points thereafter. At 62 each series is preprocessed as further detailed hereinabove. At 63, the pre-processed first series is subtracted from the pre-processed kth series ($k > 1$). At 64, a time dependence can be evaluated. For example, the signal of each pixel (or some ROI) in the maps can be calculated as a function of time post administration. A mathematical fitting procedure can be applied so as to fit the time dependence to a mathematical model. The fit can then be used for extracting information from the temporal behavior signal. For example, the fit can be used to extract permeability of the blood vessel, tissue density, and the like.

[0149] An application of the present embodiments involves depiction of tumors, particularly but not necessarily brain tumors, after treatment with anti-angiogenic treatments and studying the mechanism of action and response patterns of anti-angiogenic drugs.

[0150] A further application involves depiction of tissue disorders, particularly but not necessarily brain disorders, after treatment with radiation-based treatments, for differentiation between disease progression and radiation necrosis.

[0151] A further application of the present embodiments allows for differentiation between progression of brain space occupying lesion (SOL) and treatment effects following radio-surgical treatment.

[0152] As mentioned above, the first scan can be taken between 2 and 10 minutes, more preferably at least 5 minutes but not more than 10 minutes, after contrast injection.

[0153] As further mentioned above, better resolution may be achieved, using 3D MRI, to effectively distinguish between progression and pseudoprogression of the tumor, where pseudoprogression is most likely to be related to effects of the treatment (surgery, radiotherapy and chemotherapy).

[0154] Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.

EXAMPLES

[0155] Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non limiting fashion. The following examples demonstrate how improved management of patients is made possible by use of the present embodiments.

[0156] In the Examples below, the maps of the present embodiments are presented in colors wherein morphologically active tumors are shown in blue and non-tumoral regions are shown in red.

Example 1

[0157] Referring now to Fig. 2A, an example of newly diagnosed GBM involves 49 year old male. The patient, with newly diagnosed GBM, underwent gross total resection at Sheba Medical Center followed by chemoradiation. The patient was recruited to the present study 1 week after chemoradiation with clinical deterioration. Conventional MRI showed a large partially enhancing lesion with low rCBV (Fig. 2A top). The maps (Fig. 2A below) showed that only part of the enhancing volume (on T1-MRI) consisted of morphologically active tumor (blue):

The patient was stabilized on steroids. The neuro-oncologist was determined to continue treatment with TMZ. The neurosurgeon was concerned surgery may be necessary. Referring now to Fig. 2B, the patient was rescanned 2.5 weeks later. Conventional MRI (including T1, T2, FLAIR, DWI and DSC PWI) showed no significant change. The maps (Fig. 2B below) showed significant increase in the active tumor volume with the addition of light blue regions surrounding the enhancing regions, suspected as infiltration of tumoral vasculature:

The patient underwent a second surgery 2 days later with results shown in Fig. 3.

[0158] Histology of samples taken from various blue regions (examples pointed to by arrows in Fig. 3A) showed a highly cellular tumor in Fig. 3B. Fig. 3C shows some regions of splitting of cells, and the tumor was highly vascularized in many regions as seen in Fig. 3E.

[0159] In this patient significant light blue regions were depicted surrounding the enhancing region of the tumor (as seen in several previous cases). The only available histology of these regions has until now all been from a single patient. The histology shows infiltration of abnormal blood vessels in normal appearing brain surrounding the tumor. We believe this may be explained by abnormal vasculature in normal-appearing/infiltrative regions of surrounding brain. In this case part of the tumor was resected, showing the anatomy of the tumor and some of the surrounding brain tissue, as per Figs. 3D and 3G.

[0160] Part of this tumor was resected en-block (Fig 3F) showing the typical anatomy of the tumor, consisting of a necrotic center surrounded by a thick rim of morphologically active tumor, in excellent agreement with the calculated maps (top right).

[0161] Referring now to Fig. 4, the patient was scanned 1 month post surgery and his maps showed the surgery was successful and most of the tumor was removed;

Example 2

[0162] Newly diagnosed GBM: A 50 year old male with newly diagnosed GBM underwent gross total resection at Sheba Medical Center followed by chemoradiation. 1 month after chemoradiation, increased enhancing volume was noted on contrast-enhanced T1-MRI with no clinical deterioration. PWI was inconclusive. The patient consulted with physicians at Sheba and Hadassah Medical Centers who could not advise whether he should be operated or continue TMZ treatment since they were unable to determine if the radiological deterioration was due to tumor progression or treatment effects. Referring now to Fig. 5, the patient was recruited to our study and his maps (Fig. 5A bottom) showed significant volume of active tumor (blue) surrounding the previous surgery site:

Therefore, it was decided to re-operate on the patient.

[0163] In this case, as per Fig. 5B, histology did not show a high density tumor and very little mitosis. But there were many clusters of small cells which raised suspicions of proliferation. Fig. 5C shows regions with palisading necrosis. As shown in Fig. 5D, these regions showed abnormal blood vessels such as the glomeroid vessel below.

[0164] Later staining of these regions with ki67 showed multiple foci of proliferating cells (8-10%) confirming the diagnosis of morphologically active tumor, as shown in Fig. 5E.

[0165] The patient was re-admitted to the hospital two weeks post surgery due to wound healing problems. Conventional MRI acquired at this time showed significant new enhancing regions suspected as tumor progression, as shown in Fig. 6.

[0166] Another two weeks later (4 weeks post surgery) the patient was scanned, as in Fig. 7, and the maps showed the surgery was successful, most of the tumor had been removed and the new enhancing regions were consistent with inflammation and not with tumor.

[0167] The patient has shown significant clinical improvement and continued TMZ and follow-up.

Example 3

[0168] Recurrent GBM: Referring now to Fig. 8, a 58 year old male with recurrent GBM was recruited 7 month after diagnosis prior to initiation of Bevacizumab treatment. At diagnosis the patients was operated on and received chemoradiation followed by TMZ. Six months later, at progression, the patient underwent a second resection and was recruited to the present Bevacizumab study 1 month after the second surgery, prior to initiation of the Bevacizumab treatment. At this point his enhancing lesion consisted of nearly 50% tumor according to the maps. Three months after initiation of Bevacizumab treatment conventional MRI showed improvement but the maps showed significantly larger blue/tumor volume, consistent with clinical deterioration. Following this scan the patient was treated with re-irradiation (in parallel with continuing Bevacizumab) and was stabilized. The next follow-up showed no significant change on conventional MRI but significant treatment response in the maps (a large percentage of the blue/tumor volume turned into red/non-tumor). The patient lived another ~7 months after this last MRI scan.

Example 4

[0169] GBM - Progression vs pseudoprogression: Examples of progression are characterized in the maps by increased blue/tumor volumes, and pseudoprogression is characterized in the maps by increased red volume with stable/decreased or slower increase in the blue/tumor volume. Two examples in GBM patients post chemoradiation are given in Fig. 9.

[0170] Referring now to Fig. 9, in the first example (top row), the total enhancing volume has increased by 16% between 3 weeks (A) and 2.5 months (B) and then remained 17% above the initial volume (C) at 6.5 months post treatment. The blue volume slightly increased by 2% in the first 2.5 months (A, B) and then significantly increased to 57% above the initial volume at 6.5 months (C) while the red volume increased by 39% in the first 2.5 months (A, B) and decreased to 61% below the initial volume by 6.5 months (C). This patient progressed 6.5 months post treatment when he was referred to surgery. Histology showed -70% of the lesion to consist of active tumor in agreement with the pre-surgical maps.

[0171] In the second example (bottom row of Fig. 9), the total enhancing volume increased by 34% between 3 weeks (D) and 4.2 months (E) post chemoradiation, and then decreased to 33% below the initial volume (F) 9 months post treatment. The blue volume slightly increased by 6% in the first 4 months (D, E) and then significantly decreased to 47% below the initial volume at 9 months (F) while the red volume increased by 51% in the first 4.2 months (D, E) and decreased to 13% above the initial volume by 9 months (F). It was determined that the patient was experiencing pseudoprogression at 4.2 months. The patient progressed 11.6 months post treatment and was switched to Bevacizumab.

Example 5

[0172] Breast cancer brain metastasis: Referring now to Fig. 10, a 49 year old female with a breast cancer brain metastasis was recruited 6 months post SRS with a small blue/tumor component. In the next follow-up, 3 months later, the blue component increased significantly. The patient was operated and histology showed active tumor in agreement with the pre-surgical maps. Maps calculated from the MRI acquired 1 month post surgery showed residual tumor surrounding the surgery site. At three months post surgery the blue volume had increased. The patient received radiation therapy and in the next follow-up, 3 months post radiation therapy, there was no residual blue/tumor component. The patient is stable and continuing follow-up.

[0173] Comparison of the pre-surgical maps (B, F) with histology (C, D, G) for this patient is shown in Fig. 11. The sample taken from a red region marked by arrows in A and B shows a small tumor foci, surrounding a viable blood vessel, within a larger region of necrosis (C, magnification x100). An example of necrotic blood vessels within the necrotic region (x400) is shown in D. Another sample, taken from a blue region on the border of normal brain marked by arrows in E and F, shows a highly cellular tumor adjacent to normal cortex (G, x200).

Example 6

[0174] Melanoma brain metastasis: Referring to Fig. 12, a 57 years old female with a melanoma brain metastasis was recruited 4 months post SRS with an enhancing lesion showing red (reflecting radiation necrosis) in the maps. The patient has been followed for 13 months with no additional treatment. The lesion has nearly completely resolved.

Example 7

[0175] Reference is now made to Fig. 13 which shows an example of head and neck (extra cranial tumor) cancer, in which a patient with head and neck cancer ~1 year post chemoradiation was referred to the present inventors with a question of tumor progression versus treatment effects. The tumor is depicted in the maps (arrow, right) as mainly blue, with no red component, suggesting tumor progression and not treatment effects. The patient died a few months later.

Using different delays and 3D imaging sequences:

[0176] The maps presented above were calculated from spin-echo T1-weighted MR images of 5mm slices (with 0.5 mm gap between slices) acquired ~2 min after contrast injection and ~75 min (on average, range of 60-90 min after contrast injection) after contrast injection.

[0177] Since the contrast agent signal decays exponentially, we realized that the time of the delayed point can be flexible and the maps are not significantly changed when acquiring the late point at for example 90 min instead of 75 min post contrast.

[0178] The time of which the first images are acquired post contrast may have a larger effect on the resulting maps. For example, the signal of a lesion consisting of high concentration of normal blood vessels will increase fast after contrast injection (together with the increase of the blood due to the high concentration of the contrast agent) and will reach the maximal signal intensity within the first minute after contrast injection. Therefore, in order to obtain maximum sensitivity of the maps of the present embodiments to the change in signal intensity between the two data points it would be optimal to acquire the first data point soon after contrast injection. Since practically all our patients undergo DSC PWI during or immediately after contrast injection, the earliest we could acquire the first data point was ~2 min after contrast injection.

[0179] Still, in the case of brain tumors, there are additional factors affecting the time of the peak intensity. For example, a tumor consisting of certain BBB disruption patterns resulting in relatively slow accumulation of the contrast agent in the extracellular region, may reach the peak signal intensity of 5, 10 or even 15 min after contrast injection. In this case, it would be preferred to set the first time at some delay after contrast injection in order to maximize the difference in signal intensity between the two time points and thus increase the sensitivity to tumor tissues.

[0180] In the current study, we acquired our previously presented maps (using spin echo T1-weighted MRI with 5mm slice thickness and 0.5 mm gap) with the first time point set at 2 min post contrast injection and the second point set at

~75 min (on average) post contrast. In addition, we have acquired additional sets of T1-weighted MR images using a 3D FSPGR MR sequences acquired 4-6 min post contrast injection (early point) and ~80 min post contrast injection (late point).

[0181] Using the 3D sequence provides increased sensitivity to the tumoral tissue due to the high spatial resolution (1mm slice thickness instead of 5.5 mm) and thus increasing the sensitivity to small tumoral regions.

[0182] In addition, in some tumors which reach the peak signal intensity later after the contrast injection, the 3D maps presented larger regions (i.e. increased sensitivity to tumoral regions) than those depicted in the regular maps. Examples are shown in Fig 14, which is discussed in greater detail below.

[0183] As we generally use additional time points post contrast injection (between 2 min after contrast injection to 75 min post contrast injection) in order to obtain more information regarding the physiology of the tissues by studying the clearance/accumulation patterns of the contrast as a function of time, we may change the resolution of the 3D information in order to shorten the acquisition time at each point (for example reducing the resolution from 1mm slices to 2mm slices will cut down the acquisition time by nearly a factor of 2). This way we can still keep the 3D quality of the data but obtain more data points at relatively short acquisition times.

The advantages of using the 3D maps:

[0184] The 3D maps enable a high resolution (pixels size of $\sim 1\text{mm}^3$) depiction of tumor and non-tumoral tissues thus providing information regarding much smaller lesions and higher sensitivity to tumoral tissues than that obtained by the 2D maps. The 3D maps can also be used to obtain 3D views of the pathology thus assisting the physician in studying the pathology as well as plan high precision treatments.

[0185] The 3D maps are calculated from the 3D MRI data used for planning/performing precise procedures such as biopsies, surgeries, focused radiation therapy, implantation of devices/shunts and more. The fact that the 3D maps of the present embodiments are of the same format, the same resolution and naturally registered to the conventional 3D data used in the neuronavigation/RT-planning workstations, makes their application for these procedures straightforward. Using the same tools they used before, the physicians can now target their treatment precisely at the tumoral tissue.

[0186] As illustrated in the examples, the 3D maps do not merely provide greater resolution, but actually allow the user to distinguish more effectively between tumor and treatment changes.

Data acquisition parameters for the 3D data:

[0187] *3D T1-weighted FSPGR MR images were acquired on a 1.5T Interventional Optima General Electric MR scanner with the following parameters: TE/TR=2.1/7.4, TI=400, Flip angle 20° , 1 acquisition, 1 mm slice thickness, BW=31 KHz, Matrix 256x256, 1 slab of 80 slices with a voxel size of $0.94 \times 0.94 \times 1 \text{ mm}^3$. Total acquisition time ~6 min. 5 min after injection and 80 min post injection.

[0188] *3D T1-weighted FSPGR MR images were acquired on a 3T Signa HD XT General Electric MR scanner with the following parameters: TE/TR=3.1/7.54, TI=400, Flip angle 20° , 1 acquisition, 1 mm slice thickness, BW=31 KHz, Matrix 256x256, 1 slab of 80 slices with a voxel size of $0.94 \times 0.94 \times 1 \text{ mm}^3$. Total acquisition time ~6 min. 4 min after injection and 80 min post injection.

Example 8

[0189] Example 8 exemplifies use of 2D and 3D maps. Referring now to Fig. 14, a patient with 3 brain metastases of lung cancer was scanned by our 2D (D) and 3D (A-axial view, B-coronal view, C-sagittal view) maps. One can see the high sensitivity to the thin rim of active tumor (blue) provided by the 3D maps. The ability to view the lesions from different directions, obtained by the 3D information, makes it ideal for planning/performing high precision procedures.

Example 9

[0190] In an example of recurrent GBM post surgery, a 50 year old patient underwent subtotal gross tumor resection followed by chemoradiation and adjuvant Temozolomide. Three months after the resection, due to a recurrent tumor depicted in our maps the patient underwent a second resection. One month post surgery the maps showed no residual tumor. The maps presented in Fig. 15 were calculated from MR images acquired 3 months after the second resection showing the recurrent tumor surrounding the surgery site.

[0191] Fig. 15 shows 2D maps acquired 1 month and 3 months after the second resection showing that most of the blue/tumor tissue has been removed (1 month post surgery) but recurrence was observed 3 months post surgery.

[0192] Fig. 16 shows 2D (left) and 3D (right) maps acquired 3 months after the second resection showing recurrent tumor. It can be seen that the 3D maps (slice resolution 1 mm, 1st time point acquired 5 min post contrast injection)

show larger regions of recurrent tumor surrounding the surgery site, arrows) than the 2D maps (slice resolution 5.5 mm, 1st time point acquired 2 min post contrast injection). In addition, it is possible to see a small distant tumoral region (adjacent to the ventricle, arrow) which could not be detected in the 2D maps due to its small dimensions but is depicted in the 3D maps.

Example 10

[0193] Referring now to Fig. 17, a patient with a brain metastasis of ovarian cancer was scanned by both 2D (top) and 3D (bottom) maps. In this case the 3D maps present higher resolution but the overall tumor volume seen in the two types of maps is similar.

Example 11

[0194] This Example demonstrate the ability of the present embodiments to differentiate open arteriovenous malformation (AVM) from closed AVM and from treatment effects.

[0195] Nine patients with AVM were recruited. Examples of three treated lesions are shown in FIGs. 18A-I. Blood vessels appear blue in the maps and treatment effects such as radiation necrosis appear red. FIGs. 18A-C (top row) show contrast-enhanced T1-weighted MRI, FIGs. 18D-F (middle row) show the calculated maps, and FIGs. 18G-I (bottom row) show rCBV maps.

[0196] FIGs. 18A-I demonstrate patients with arteriovenous malformation, 3.5 years after 5 embolization treatments (FIGs. 18A, 18D, 18G), 2 weeks after stereotactic radiosurgery (FIGs. 18B, 18E, 18H) and 3 years after embolization and fractional stereotactic radiosurgery (FIGs. 18C, 18F, 18I).

[0197] Blue regions in the maps thus represent open AVM regions. FIGs. 18A-I shows an example of a closed AVM (left column) an open AVM (middle column) and a partially open AVM with radiation necrosis (right column).

[0198] Other vascular disorders can be analyzed using the same or similar techniques. For example, the technique allows depiction of cavernoma within a bleeding region.

Example 12

[0199] This example demonstrates the ability of the present embodiments to differentiate tumor from treatment effects, in cases of rare tumors.

[0200] An 8 years old boy was recruited with an anaplastic chordoma, previously treated by stereotactic radiosurgery and now showing increased enhancement suspected for radiation necrosis. FIG. 19 shows the obtained MRI (top row) and the constructed maps (bottom row). The maps show significant portion of active tumor. The boy was referred to surgery.

[0201] A 63 years old patient recruited 1 year after stereotactic radiosurgery of a chordoma with suspected radiation necrosis. FIG. 20A shows the obtained MRI and FIG. 20B shows the constructed map. The map shows radiation necrosis.

[0202] A patient was recruited 3 years after stereotactic surgery treatment of anaplastic meningioma with a question of tumor versus treatment effects. FIG. 21A shows the obtained MRI and FIG. 21B shows the constructed map. The map show significant component of active tumor and the patient was resected.

[0203] A patient previously diagnosed with a low grade non-enhancing glioma in the brain stem and spine, recruited to the study with new enhancements in the spine suspected for radiation necrosis. FIGs. 22A and 22C show the obtained MRI and FIGs. 22B and 22D show the constructed maps. One lesion was determined by the maps to be active tumor (FIG. 22B) while the other was determined to be treatment effects (FIG. 22D).

[0204] A patient was recruited 1 month after surgical removal of a hypofisal adenoma with a question of residual tumor post surgery. FIG. 23A shows the obtained MRI and FIG. 23B shows the constructed map. The map allows determining the existence of residual tumor.

[0205] A patient with petroclival meningioma was recruited 6 years post SRS with a question of tumor versus radiation necrosis. FIG. 24A shows the obtained MRI and FIG. 24B shows the constructed map. The map shows significant volumes of active tumor.

Example 13

[0206] This example demonstrate the application of the maps of the present embodiments for animals. FIG. 25A shows MRI obtained from rats with CNS1 glioma, and FIG. 25B shows the respective constructed map. FIGs. 26B and 26D show MRI obtained from dogs with spontaneous glioma, and FIGs. 26A and 26C show the respective constructed maps. FIG. 27A shows MRI obtained from nude mice with U87 (human) glioma, and FIG. 27B shows the respective constructed map.

Example 14

[0207] This example demonstrates the ability of the maps of the present embodiments to detect active tumor within bleeding regions.

5 [0208] A patient with malignant melanoma was recruited after diagnosis of a bleeding lesion in the brain stem with a question of existence of active tumor within the bleeding region.

[0209] FIG. 28A shows MRI (top row) and constructed maps (bottom row) obtained before treatment, and FIG. 28B shows MRI (top row) and constructed maps (bottom row) obtained four months after treatment by radiation. The maps show significant tumor volume within the bleeding prior to treatment and four months following treatment the tumor volume decreased significantly.

Example 15

15 [0210] This example demonstrates the ability of the maps of the present embodiments to monitor the response of breast cancer brain metastases to Avastin. In addition, this example demonstrates the advantage of the maps over conventional MRI in studying the action of the drug. There is current dispute whether Avastin affects active tumor or only treatment effects. The current example demonstrates the ability of the maps to show that the drug had direct effect on the tumor component and not only on the treatment effects component.

20 [0211] A patient with cerebellar metastasis of breast cancer was recruited 2 years after stereotactic radiosurgery with suspected radiation necrosis. FIG. 29A shows MRI (top row) and constructed maps (bottom row) obtained before treatment, and FIG. 29B shows MRI (top row) and constructed maps (bottom row) obtained after treatment with Avastin.

[0212] The maps showed significant tumor and radiation necrosis before treatment, and remarkable response of both components following treatment.

Example 16

25 [0213] This example demonstrates the ability of the maps of the present embodiments to monitor the response of GBM to Avastin.

[0214] A patient with GBM was recruited after 2 resections and treatment with chemoradiation.

30 [0215] FIG. 30A shows MRI (top row) and constructed maps (bottom row) obtained before treatment, and FIG. 30B shows MRI (top row) and constructed maps (bottom row) obtained after treatment. The maps show both the tumor and the treatment-effects components.

Example 17

35 [0216] Histological evaluations of 51 lesions resected from 47 patients were compared with the pre-surgical maps. In addition, 7 of the lesions were resected en-block and 62 biopsied samples were obtained from 21 of the patients. Histological data of 29 lesions obtained from 12 patients with primary brain tumors and 15 patients with metastatic brain tumors are listed in Table 1. Histological evaluation consisted of blinded pathological reports, focused mainly on the existence/absence of active tumor in all the material examined by the pathologist, and non-blinded histological evaluation of the biopsies and en-block samples.

40 [0217] Taking into account the blinded radiological reports, complete agreement between the pre-surgical maps of the present embodiments and histology was found in 47 of 51 resected lesions suggesting sensitivity and positive predictive value (PPV) to active tumor of 100% and 92% respectively. Adding the non-blinded data of 62 biopsied samples and 7 en-block samples, resulted in sensitivity and PPV of 99% and 95% respectively. Disagreement between the maps of the present embodiments and histology were found in 4 cases. In 3 cases of brain metastases, the pre-surgical maps showed ~85% red and ~15% blue while no tumor was found in histology. Still, a blue rim surrounding the surgery site appeared 1-4 months post-surgery in all 3 patients suggesting residual/recurrent tumor. The fourth case was of a GBM patient who underwent gross total resection 4 months prior to recruitment followed by one course of radiation and one course of TMZ. In this case the maps of the present embodiments showed a blue/tumor volume of 3.3 ml at recruitment and of 12.8 ml 2 months later, prior to surgery. Despite the rapid growth in blue/tumor volume, histology determined the tumor to be quiescent.

EP 2 988 668 B1

Table 1

List of biopsied and whole samples, maps characteristics and histological evaluation					
Sample #	Lesion #	Patient #	map characteristics	Histological description	Clinical diagnosis
1	1	1	Sample taken from medial blue region	Cellular tumor with dilated blood vessels with thick walls	AA post chemoradiation
2	1	1	Sample taken from lateral blue region	Cellular tumor	AA post chemoradiation
3	1	1	Sample taken from periventricular blue region	Cellular tumor with dilated blood vessels	AA post chemoradiation
4	1	1	Sample taken from central red region	Mostly radiation necrosis with reactive astrocytes. There are small regions with non-active tumor	AA post chemoradiation
1	2	2	Sample taken from lower blue region	Highly cellular active tumor	GBM post chemoradiation
2	2	2	Sample taken from higher blue region	Highly cellular active tumor	GBM post chemoradiation
1	3	3	Sample taken from light blue region adjacent to the periphery of the tumor	atypical cells and proliferating blood vessels in the infiltrating zone	GBM post chemoradiation
2	3	3	Sample taken from blue region in the deep frontal region of the tumor mass	highly cellular and highly vascularized tumor and cellular atypia	GBM post chemoradiation
3	3	3	Sample taken from central red region on the border of a blue region	a large necrotic region bordered by a highly vascularized tumor	GBM post chemoradiation
4	3	3	Sample taken on the border between a blue region and adjacent light blue region in surrounding brain	active tumor and abnormal vessels in the peripheral/infiltrating region	GBM post chemoradiation

EP 2 988 668 B1

(continued)

List of biopsied and whole samples, maps characteristics and histological evaluation					
Sample #	Lesion #	Patient #	map characteristics	Histological description	Clinical diagnosis
5	3	3	Sample taken from light blue region surrounding the tumor and adjacent to the ventricles	normal brain and infiltrating zone with abnormal blood vessels	GBM post chemoradiation
10	3	3	Sample taken en-block from a region showing a red center surrounded by a thick blue rim	En-block sample: Central necrotic region surrounded by highly cellular and highly vascularized rim of tumor	GBM post chemoradiation
15	4	4	Sample taken from lower blue region	Active tumor showing hypercellularity, cellular atypia and mitoses	GBM post chemoradiation
20	4	4	Sample taken from anterior blue region	Active tumor showing hypercellularity, cellular atypia and mitoses	GBM post chemoradiation
25	4	4	Sample taken from superior blue region	Active tumor showing hypercellularity with cellular atypia, mitoses, vascular proliferation and pseudopalisading necrosis	GBM post chemoradiation
30	4	4	Sample from posterior blue region	Active tumor showing hypercellularity, cellular atypia and mitoses	GBM post chemoradiation
35	5	5	Sample taken from blue peripheral region	Highly cellular active tumor	Malignant melanoma brain metastasis
40	5	5	Sample taken from central red/green region adjacent to surrounding blue region	Necrosis and hemorrhages on the border of the tumor region	Malignant melanoma brain metastasis
45	6	6	Sample taken from blue peripheral region reaching the dura	Active tumor adjacent to the dura	Malignant melanoma brain metastasis
50	6	6	Sample taken from a blue region within the main tumor mass	Active tumor with dilated blood vessels	Malignant melanoma brain metastasis
55					

EP 2 988 668 B1

(continued)

List of biopsied and whole samples, maps characteristics and histological evaluation					
Sample #	Lesion #	Patient #	map characteristics	Histological description	Clinical diagnosis
3	6	6	Sample taken from a blue region at the medial peripheral region of the tumor mass	Active tumor with dilated blood vessels	Malignant melanoma brain metastasis
1	7	7	Sample taken from frontal blue region	Active tumor with small regions of necrosis	GBM post chemoradiation
2	7	7	Sample taken from frontal red region	necrosis	GBM post chemoradiation
3	7	7	Sample taken from posterior red region	necrosis	GBM post chemoradiation
4	7	7	Sample taken from lower region of mixed red/blue	Necrosis with regions of active tumor	GBM post chemoradiation
1	8	8	Sample taken from peripheral blue region	Active lymphoma tumor	Diffuse large B cell lymphoma
1	9	9	Sample taken from lateral blue region	Highly cellular tumor with multiple foci of palicadig necrosis	GBM post Avastin
2	9	9	Sample taken from lateral blue region	Highly cellular tumor with multiple foci of palicadig necrosis	
3	9	9	Sample taken from red region within a larger blue region	Scattered pieces of tissue with one region of necrosis and the rest tumor	
4	9	9	Sample taken from central blue region	Highly cellular tumor with mitosis and palicading necrosis	
1	10	10	Non-biopsied lesion: Mixed regions of blue and red surrounding the previous surgery site	Active tumor is represented by moderately cellular areas with numerous gemistocytes showing palisading necrosis. Mitoses are not detected but ki67 is positive in numerous small clusters of cells within the areas showing palisading necrosis. A proliferation of up to 8-10% of the cells is seen in these clusters. Radiation necrosis and changes are also present	GBM post chemoradiation

EP 2 988 668 B1

(continued)

List of biopsied and whole samples, maps characteristics and histological evaluation					
Sample #	Lesion #	Patient #	map characteristics	Histological description	Clinical diagnosis
1	11	11	Non-biopsied lesion: Mixed blue/red regions	Glioblastoma showing vascular proliferation and tumor necrosis	GBM post Avastin
1	12	12	Non-biopsied lesion: Mostly blue regions surrounding the previous surgery site	Anaplastic oligodendroglioma. WHO grade III. The tumor shows brisk mitotic activity, vascular proliferation and necrosis	Anaplastic oligodendroglioma.
1	13	13	Non-biopsied lesion: Red lesion surrounded by a thin blue rim (16% of the lesion volume)	Pure radiation necrosis	Breast cancer brain metastasis
1	14	14	Non-biopsied lesion: lesion consisting of 24% blue regions	Lesion consisting radiation necrosis and ~15% active tumor	Breast cancer brain metastasis
1	15	15 (1 st operation)	Non-biopsied lesion: Lesion consisting of 46% blue regions	Lesion consisting of ~50% active tumor and ~50% radiation necrosis	Breast cancer brain metastasis
1	16	15 (2 nd operation)	Non-biopsied lesion: lesion showing red with thin blue rim	Active tumor was found	Breast cancer brain metastasis
1	17	16	Non-biopsied lesion: Lesion with central red core surrounded by a thick blue rim	Central necrosis surrounded by active tumor	Non Small Cell Lung Cancer brain metastasis Lesion resected en-block
1	18	17	Non-biopsied lesion: Red lesion surrounded by a thin blue rim (16% of the lesion volume)	Pure RN	Non Small Cell Lung Cancer brain metastasis
1	19	18 (1 st operatopm)	Non-biopsied lesion: Blue lesion with a red center	Metastatic squamous cell carcinoma	Non Small Cell Lung Cancer brain metastasis Lesion resected en-block

EP 2 988 668 B1

(continued)

List of biopsied and whole samples, maps characteristics and histological evaluation					
Sample #	Lesion #	Patient #	map characteristics	Histological description	Clinical diagnosis
1	20	18 (2 nd operation)	Non-biopsied lesion: Lesion within previous surgery site, mostly blue	Squamous cell carcinoma from lung with less differentiations and spindling than in the previous surgery	Non Small Cell Lung Cancer brain metastasis Lesion resected en-block
1	21	19	Non-biopsied lesion: Mostly blue lesion	Adeno carcinoma is present	Adeno carcinoma of unknown source
1	22	20	Non-biopsied lesion: Large lesion, mixed blue, red, green	Papillary tumor, radiation necrosis and hemorrhages are present	Non Small Cell Lung Cancer brain metastasis
1	23	21	Non-biopsied lesion: Mostly blue lesion	Metastatic carcinoma is present	Non Small Cell Lung Cancer brain metastasis
1	24	22	Non-biopsied lesion: Mostly blue lesion	Active tumor is present, with regions of dilated tumor vessels and hemorrhages within the tumor with adjacent normal brain	Malignant melanoma brain metastasis Lesion resected en-block
1	25	23	Non-biopsied lesion: Red lesion with thin blue rim (16% of the lesion volume)	Mainly brain fragments with reactive changes and some fragments of pure radiation necrosis	Non Small Cell Lung Cancer brain metastasis
1	26	24	Non-biopsied lesion: Blue lesion extending to a red lesion surrounded by a thin blue rim	Active tumor is present	Non Small Cell Lung Cancer brain metastasis Lesion resected en-block
1	27	25	Non-biopsied lesion: Red lesion with a thin blue rim	Active tumor is present	Yolk Sac Carcinoma brain metastasis Lesion resected en-block
1	28	26	Non-biopsied lesion: Lesion consisting of a red rim surrounded by a blue rim	Meningioma with necrotic area. Atypical meningioma WHO grade II. EMA positive. Ki67 positive in ~25% of the cells. CD34 focally positive. BCl2 and PR negative.	Atypical meningioma
1	29	27	Non-biopsied lesion: Mostly blue mass surrounding previous surgery site	Quiescent tumor with very little regions of RN. Hypercellularity due to the presence of histiocytes and hyperplasia of microglia and scattered non-proliferating small cells of uncertain identity. In addition, large radiated tumor astrocytes.	GBM post chemoradiation

[0218] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

[0219] Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the scope of the appended claims.

Claims

1. Apparatus for operating MRI, comprising:

a control for operating an MRI scanner to carry out an MRI scan of an organ of a subject;
 an input for receiving first and second MRI scans respectively at the beginning and end of a predetermined time interval post contrast administration;
 a subtraction map former for forming a subtraction map from said first and said second MRI scans by subtracting said scans to distinguish between two primary populations, said two primary populations comprising a population in which, during said time interval, contrast clearance from the tissue is slower than contrast accumulation, and a population in which, during said time interval, clearance is faster than accumulation; and
 an output to provide an indication of distribution of said two primary populations,
characterised in that said control is configured to carry out said first scan at least five minutes and no more than twenty minutes post contrast administration and to carry out said second scan such that said predetermined time interval is at least twenty minutes.

2. The apparatus according to claim 1, wherein said predetermined time interval is any one of the group consisting of: more than twenty minutes, more than thirty minutes, more than forty minutes, more than fifty minutes, more than sixty minutes, more than seventy minutes, more than eighty minutes, more than ninety minutes, more than a hundred minutes, seventy minutes, seventy five minutes and ninety minutes.

3. The apparatus according to any of claims 1-2, wherein said population in which said contrast clearance is slower than contrast accumulation corresponds to an abnormal but non-tumoral tissue region.

4. The apparatus according to claim 3, wherein said abnormal but non-tumoral tissue region corresponds to at least one of a treatment effect, an inflammation, and BBB disruption.

5. The apparatus according to any of claims 1-4, further configured to carry out image pre-processing, said image pre-processing preferably comprising at least one of registration and correction for intensity variations.

6. The apparatus of claim 5, wherein said correction for intensity variations comprises calculating, for each MRI image separately, an intensity variation map consisting of large scale intensity variations therein and then subtracting said intensity variation map from the respective image.

7. The apparatus according to claim 5, wherein said registration comprises at least one of a rigid body registration, and an elastic registration to allow for head movements and resulting distortions between respective scans.

8. The apparatus according to any of claims 1-7, further comprising a data processor configured for estimating a progression time of a tumor, based on initial growth rate in said population in which clearance is faster than accumulation.

9. The apparatus according to claim 1, in use for depiction of a space occupying lesion (SOL) in said organ after treatment, for differentiation between disease progression and treatment effects.

10. The apparatus according to any of claims 1-8, wherein said MRI is of a subject diagnosed with GBM, wherein said subtraction map former is configured to identify changes in a volume of said population in which clearance is faster than accumulation, and wherein said output is configured to indicate progression when said increment is above a predetermined threshold.

11. Method for analyzing MRI of an organ of a subject, comprising:

receiving a first and a second MRI scan acquired at the beginning and end of a predetermined time interval post contrast administration, wherein the time interval begins at least five minutes and no more than ten minutes post contrast injection, wherein said receiving does not include imaging the organ;
 forming a subtraction map from said first and said second MRI scans by analyzing said scans to distinguish between two primary populations, said two primary populations comprising a population in which, during said time interval, contrast clearance from the tissue is slower than contrast accumulation, and a population in which, during said time interval, clearance is faster than accumulation; and
 providing on an output an indication of distribution of said two primary populations, wherein said predetermined time interval is at least twenty minutes.

12. The method of claim 11, wherein said MRI scans are 3D MRI scans.

13. The method according to any of claims 11 and 12, further comprising determining, from said subtraction map, whether tumour tissue is present, by comparing drainage of the contrast agent from blood vessels with contrast agent take up in the tissue.

14. The apparatus or method according to any of claim 11-13, in use for differentiating between morphologically active tumor represented by said population in which clearance is faster than accumulation, and a non-tumoral tissue represented by said population in which clearance is slower than accumulation.

15. The apparatus or method according to any of claims 1-14, wherein said organ is selected from the group consisting of brain, colon, prostate, bladder, breast, chest, lung, liver, bones and bone marrow, ovary, kidneys, spleen, thyroid gland, pancreas, head and neck, extremities, skin, lymph nodes, brain, colon, prostate, breast, lung, liver, bones and bone marrow, ovary, pancreas, head and neck, skin, abdomen, eyes, heart, stomach.

16. The apparatus or method according to any of the preceding claims, in use for at least one of: depiction of residual tumor post surgery, distinguish between residual tumor post-surgery and post-surgical changes, guiding a local treatment of tumor, detecting active tumor within bleeding regions, differentiating malignant transformation from treatment effects in treated low grade tumors, depiction of tumors in said organ after treatment with anti-angiogenic treatments and studying the mechanism of action and response patterns of anti-angiogenic drugs, depiction of tumors in said organ after treatment with radiation-based treatments, for differentiation between tumor progression and radiation necrosis, depiction of tumors in said organ after treatment with radiation-based chemotherapy and/or treatments for differentiation between tumor progression and pseudoprogression, differentiation between progression of brain space occupying lesion (SOL) and treatment effects following focused radiation treatments, identifying change in a volume of said population in which clearance is faster than accumulation, wherein a level of increment above a predetermined threshold indicates tumor progression, and differentiating open AVM from at least one of closed AVM and treatment effects.

Patentansprüche

1. Vorrichtung für MRI-Betrieb, welche aufweist:

eine Steuerung zum Betreiben eines MRI-Scanners zur Ausführung eines MRI-Scans eines Organs eines Probanden;
 einen Eingang zum Erhalten erster und zweiter MRI-Scans jeweils zu Beginn und Ende eines vorbestimmten Zeitintervalls nach Kontrastmittelverabreichung;
 einen Subtraktionskartenformer zum Formen einer Subtraktionskarte aus den ersten und zweiten MRI-Scans durch Subtrahieren der Scans, um zwischen zwei primären Populationen zu unterscheiden, wobei die zwei primären Populationen eine Population aufweisen, in der während des Zeitintervalls Kontrastmittelklärung von dem Gewebe langsamer ist als Kontrastmittelakkumulation, sowie eine Population, in der während des Zeitintervalls Klärung schneller als Akkumulation ist; und
 einen Ausgang zum Liefern einer Verteilungsindikation der zwei primären Populationen,
dadurch gekennzeichnet, dass die Steuerung konfiguriert ist, um den ersten Scan wenigstens fünf Minuten und nicht mehr als zwanzig Minuten nach Kontrastmittelverabreichung auszuführen, und den zweiten Scan derart auszuführen, dass das vorbestimmte Zeitintervall wenigstens zwanzig Minuten beträgt.

2. Die Vorrichtung nach Anspruch 1, wobei das vorbestimmte Zeitintervall eines der Gruppe ist, bestehend aus: mehr als zwanzig Minuten, mehr als dreißig Minuten, mehr als vierzig Minuten, mehr als fünfzig Minuten, mehr als sechzig Minuten, mehr als siebenzig Minuten, mehr als achtzig Minuten, mehr als neunzig Minuten, mehr als hundert Minuten, siebenzig Minuten, fünfundsiebzig Minuten und neunzig Minuten.
- 5
3. Die Vorrichtung nach einem der Ansprüche 1 bis 2, wobei die Population, in der die Kontrastmittelklärung langsamer als Kontrastmittelakkumulation ist, einem abnormalen aber nicht tumorösen Gewebereich entspricht.
- 10
4. Die Vorrichtung nach Anspruch 3, wobei der abnormale aber nicht tumoröse Gewebereich wenigstens einem von Behandlungseffekt, Entzündung und BBB-Disruption entspricht.
- 15
5. Die Vorrichtung nach einem der Ansprüche 1 bis 4, die ferner konfiguriert ist, um Bildvorverarbeitung auszuführen, wobei die Bildvorverarbeitung bevorzugt zumindest eine von Registrierung und Korrektur von Intensitätsveränderungen aufweist.
- 20
6. Die Vorrichtung von Anspruch 5, wobei die Korrektur von Intensitätsveränderungen aufweist, für jedes MRI-Bild separat ein Intensitätsveränderungskennfeld zu berechnen, das aus starken Intensitätsveränderungen darin besteht, und dann das Intensitätsveränderungskennfeld von dem jeweiligen Bild zu subtrahieren.
- 25
7. Die Vorrichtung von Anspruch 5, wobei die Registrierung zumindest eines von Festkörper-Registrierung und elastischer Registrierung aufweist, um Kopfbewegungen und resultierende Verzerrungen zwischen jeweiligen Scans zu erlauben.
- 30
8. Die Vorrichtung nach einem der Ansprüche 1 bis 7, wobei die ferner einen Datenprozessor aufweist, der konfiguriert ist, um eine Progressionszeit eines Tumors basierend auf einer anfänglichen Wachstumsrate in der Population, in der Klärung schneller ist als Akkumulation, zu setzen.
- 35
9. Die Vorrichtung nach Anspruch 1 zur Verwendung zur Abbildung einer raumfordernden Läsion (SOL) in dem Organ nach Behandlung zur Differenzierung zwischen einer Erkrankungsprogression und Behandlungseffekten.
- 40
10. Die Vorrichtung nach einem der Ansprüche 1 bis 8, wobei das MRI von einem mit GBM diagnostizierten Probanden ist, wobei das Subtraktionskennfeld ferner konfiguriert ist, um Volumenänderungen der Population zu identifizieren, in der Klärung schneller als Akkumulation ist, und wobei der Ausgang konfiguriert ist, um Progression anzuzeigen, wenn das Inkrement über einem vorbestimmten Schwellenwert liegt.
- 45
11. Verfahren zur MRI-Analyse eines Organs eines Probanden, welches aufweist:
- Erhalten eines ersten und eines zweiten MRI-Scans, die zu Beginn und Ende eines vorbestimmten Zeitintervalls nach Kontrastmittelverabreichung erfasst werden, wobei das Zeitintervall wenigstens fünf Minuten und nicht mehr als zehn Minuten nach Kontrastmittelinjektion beginnt, wobei das Erhalten das Abbilden des Organs nicht beinhaltet;
- Bilden einer Subtraktionskarte von den ersten und zweiten MRI-Scans durch Analyse der Scans zum Unterscheiden zwischen zwei primären Populationen, wobei die zwei primären Populationen eine Population aufweisen, in der, während des Zeitintervalls, Kontrastmittelklärung von dem Gewebe langsamer ist als Kontrastmittelakkumulation, sowie eine Population, in der während des Zeitintervalls Klärung schneller als Akkumulation ist; und
- Bereitstellen eines Ausgangs einer Indikation der Verteilung der zwei primären Populationen, wobei das vorbestimmte Zeitintervall wenigstens zwanzig Minuten beträgt.
- 50
12. Das Verfahren von Anspruch 11, wobei die MRI-Scans 3D-MRI-Scans sind.
- 55
13. Das Verfahren von einem der Ansprüche 11 und 12, das ferner aufweist, aus der Subtraktionskarte zu bestimmen, ob Tumorgewebe vorhanden ist, durch Vergleichen der Drainage des Kontrastmittels aus Blutgefäßen mit Kontrastmittelaufnahme im Gewebe.
14. Die Vorrichtung oder das Verfahren nach einem der Ansprüche 11 bis 13 zur Verwendung zum Differenzieren zwischen morphologisch aktivem Tumor, der durch die Population repräsentiert wird, indem Klärung schneller als Akkumulation ist, und nicht tumorösem Gewebe, das durch die Population repräsentiert wird, in der Klärung lang-

samer als Akkumulation ist.

- 5 15. Die Vorrichtung oder das Verfahren nach einem der Ansprüche 1 bis 14, wobei das Organ ausgewählt ist aus der Gruppe bestehend aus Gehirn, Darm, Prostata, Blase, Brust, Brustkorb, Lunge, Leber, Knochen und Knochenmark, Ovarien, Nieren, Milz, Schilddrüse, Pankreas, Kopf und Hals, Extremitäten, Haut, Lymphknoten, Gehirn, Darm, Prostata, Brust, Lunge, Leber, Knochen und Knochenmark, Ovarien, Pankreas, Kopf und Hals, Haut, Abdomen, Augen, Herz, Magen.
- 10 16. Die Vorrichtung oder das Verfahren nach einem der vorhergehenden Ansprüche, zur Verwendung für zumindest eines von: Abbildung von postoperativem Resttumor, Unterscheiden zwischen postoperativem Resttumor und postoperativen Veränderungen, Führen einer lokalen Tumorbehandlung, Detektieren von aktivem Tumor mit blutenden Bereichen, Differenzieren zwischen maligner Transformation von Behandlungseffekten in behandelten niedriggraden Tumoren, Abbildung von Tumoren in dem Organ nach Behandlung mit anti-angiogenen Behandlungen und Untersuchung des Mechanismus von Aktions- und Reaktionsmustern von antiangiogenen Medikamenten, Abbilden von Tumoren in dem Organ nach Behandlung einer strahlungs-basierten Behandlung zur Differenzierung zwischen Tumorprogression und Strahlungsnekrose, Abbildung von Tumoren in dem Organ nach Behandlung mit strahlungs-basierter Chemotherapie und/oder Behandlungen zur Differenzierung zwischen Tumorprogression und Pseudoprogression, Differenzierung zwischen Progression von raumfordernder Gehirnläsion (SOL) und Behandlungseffekten nach fokussierten Strahlungsbehandlungen, Identifizieren einer Volumenänderung der Population, in der Klärung schneller als Akkumulation ist, wobei ein Inkrementgrad über einem vorbestimmten Schwellenwert Tumorprogression angibt, und Differenzieren von offenem AVM von geschlossenem AVM und/oder Behandlungseffekten.

25 Revendications

1. Appareil de fonctionnement d'IRM, comprenant :

30 une commande pour faire fonctionner un scanner IRM afin de réaliser un examen par IRM d'un organe d'un sujet ;
une entrée pour recevoir des premier et deuxième examens par IRM respectivement au début et à la fin d'un intervalle de temps prédéterminé après l'administration de produit de contraste ;
un dispositif de formation de carte de soustraction pour former une carte de soustraction à partir desdits premier et deuxième examens par IRM en soustrayant lesdits examens pour distinguer entre deux populations primaires, lesdites deux populations primaires comprenant une population dans laquelle, pendant ledit intervalle de temps, la clairance de produit de contraste du tissu est plus lente que l'accumulation de produit de contraste et une population dans laquelle, pendant ledit intervalle de temps, la clairance est plus rapide que l'accumulation ; et une sortie pour fournir une indication de répartition desdites deux populations primaires,

caractérisé en ce que

35 ladite commande est configurée pour réaliser ledit premier examen au moins cinq minutes et pas plus de vingt minutes après l'administration de produit de contraste et pour réaliser ledit deuxième examen de sorte que ledit intervalle de temps prédéterminé soit d'au moins vingt minutes.

- 40 2. Appareil selon la revendication 1, dans lequel ledit intervalle de temps prédéterminé est un intervalle de temps quelconque du groupe consistant en : plus de vingt minutes, plus de trente minutes, plus de quarante minutes, plus de cinquante minutes, plus de soixante minutes, plus de soixante-dix minutes, plus de quatre-vingts minutes, plus de quatre-vingt-dix minutes, plus de cent minutes, soixante-dix minutes, soixante-quinze minutes et quatre-vingt-dix minutes.
- 45 3. Appareil selon l'une des revendications 1 et 2, dans lequel ladite population dans laquelle ladite clairance de produit de contraste est plus lente que l'accumulation de produit de contraste correspond à une région de tissu anormal mais non tumoral.
- 50 4. Appareil selon la revendication 3, dans lequel ladite région de tissu anormal mais non tumoral correspond à au moins l'un(e) d'un effet de traitement, d'une inflammation et d'une rupture de BHE.
- 55 5. Appareil selon l'une des revendications 1 à 4, configuré en outre pour réaliser un prétraitement d'image, ledit prétraitement d'image comprenant de préférence au moins l'un(e) d'un enregistrement et d'une correction de variations d'intensité.

EP 2 988 668 B1

6. Appareil de la revendication 5, dans lequel ladite correction des variations d'intensité comprend le calcul, pour chaque image IRM séparément, d'une carte de variation d'intensité consistant en des variations d'intensité à grande échelle dans celle-ci et ensuite la soustraction de ladite carte de variation d'intensité de l'image respective.
- 5 7. Appareil selon la revendication 5, dans lequel ledit enregistrement comprend au moins l'un d'un enregistrement de corps rigide et d'un enregistrement élastique pour permettre des mouvements de la tête et des distorsions résultantes entre les examens respectifs.
- 10 8. Appareil selon l'une des revendications 1 à 7, comprenant en outre un processeur de données configuré pour estimer un temps de progression d'une tumeur, sur la base d'un taux de croissance initial dans ladite population dans laquelle la clairance est plus rapide que l'accumulation.
- 15 9. Appareil selon la revendication 1, en cours d'utilisation pour une représentation d'une lésion occupant l'espace (SOL) dans ledit organe après traitement, pour la différenciation entre la progression d'une maladie et les effets de traitement.
- 20 10. Appareil selon l'une des revendications 1 à 8, dans lequel ladite IRM concerne un sujet diagnostiqué comme ayant un GBM, où ledit dispositif de formation de carte de soustraction est configuré pour identifier les changements d'un volume de ladite population dans lesquelles la clairance est plus rapide que l'accumulation, et où ladite sortie est configurée pour indiquer une progression lorsque ledit incrément est supérieur à un seuil prédéterminé.
- 25 11. Procédé d'analyse d'IRM d'un organe d'un sujet, comprenant les étapes consistant :
- à recevoir des premier et deuxième examens par IRM acquis au début et à la fin d'un intervalle de temps prédéterminé après l'administration de produit de contraste, où l'intervalle de temps commence au moins cinq minutes et pas plus de dix minutes après l'injection de produit de contraste, où ladite réception ne comporte pas l'imagerie de l'organe ;
- 30 à former une carte de soustraction à partir desdits premier et deuxième examens par IRM en analysant lesdits examens pour distinguer entre deux populations primaires, lesdites deux populations primaires comprenant une population dans laquelle, pendant ledit intervalle de temps, la clairance de produit de contraste du tissu est plus lente que l'accumulation de produit de contraste, et une population dans laquelle, pendant ledit intervalle de temps, la clairance est plus rapide que l'accumulation ; et
- à fournir sur une sortie une indication de répartition desdites deux populations primaires, où ledit intervalle de temps prédéterminé est d'au moins vingt minutes.
- 35 12. Procédé de la revendication 11, dans lequel lesdits examens par IRM sont des examens par IRM 3D.
- 40 13. Procédé selon l'une des revendications 11 et 12, comprenant en outre l'étape consistant à déterminer, à partir de ladite carte de soustraction, si un tissu tumoral est présent, en comparant le drainage de l'agent de contraste des vaisseaux sanguins à l'assimilation d'agent de contraste dans le tissu.
- 45 14. Appareil ou procédé selon l'une des revendications 11 à 13, en cours d'utilisation pour la différenciation entre une tumeur morphologiquement active représentée par ladite population dans laquelle la clairance est plus rapide que l'accumulation, et un tissu non tumoral représenté par ladite population dans laquelle la clairance est plus lente que l'accumulation.
- 50 15. Appareil ou procédé selon l'une des revendications 1 à 14, dans lequel ledit organe est choisi dans le groupe consistant en le cerveau, le côlon, la prostate, la vessie, le sein, la poitrine, le poumon, le foie, les os et la moelle osseuse, l'ovaire, les reins, la rate, la glande thyroïde, le pancréas, la tête et le cou, les membres, la peau, les ganglions lymphatiques, le cerveau, le côlon, la prostate, le sein, le poumon, le foie, les os et la moelle osseuse, l'ovaire, le pancréas, la tête et le cou, la peau, l'abdomen, les yeux, le coeur, l'estomac.
- 55 16. Appareil ou procédé selon l'une des revendications précédentes, en cours d'utilisation pour au moins l'un(e) parmi : une représentation d'une tumeur résiduelle après une intervention chirurgicale, une distinction entre une tumeur résiduelle après une intervention chirurgicale et les changements postopératoires, un guidage d'un traitement local de la tumeur, une détection d'une tumeur active dans des régions sanguinolentes, une différenciation de transformation maligne des effets de traitement dans les tumeurs de faible grade traitées, une représentation de tumeurs dans ledit organe après traitement avec des traitements anti-angiogéniques et une étude du mécanisme d'action

EP 2 988 668 B1

et des schémas de réponse des médicaments anti-angiogéniques, une représentation de tumeurs dans ledit organe après traitement avec des traitements basés sur les rayonnements, pour une différenciation entre la progression tumorale et une radionécrose, une représentation de tumeurs dans ledit organe après traitement avec une chimiothérapie et/ou des traitements basé(e)s sur les rayonnements pour une différenciation entre la progression tumorale et la pseudoprogession, une différenciation entre la progression de lésion occupant l'espace cérébral (SOL) et les effets de traitement après des traitements par rayonnement focalisé, une identification de changement d'un volume de ladite population dans laquelle la clairance est plus rapide que l'accumulation, où un niveau d'incrément supérieur à un seuil prédéterminé indique la progression tumorale, et une différenciation d'AVM ouverte d'au moins l'un(e) d'AVM fermée et des effets de traitement.

5

10

15

20

25

30

35

40

45

50

55




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 1E




FIG. 1F




FIG. 2A




FIG. 2B




FIG. 3B




FIG. 3D




FIG. 3A




FIG. 3C




FIG. 3F




FIG. 3H




FIG. 3E




FIG. 3G




FIG. 4




FIG. 5A




FIG. 5C




FIG. 5E




FIG. 5B




FIG. 5D




FIG. 6




FIG. 7




FIG. 8

FIG. 9A FIG. 9B FIG. 9B




FIG. 9D FIG. 9E FIG. 9F




FIG. 10




FIG. 11





FIG. 13



17 months post SRS

4 months post SRS

FIG. 12




FIG. 14




FIG. 15




FIG. 16




FIG. 17

FIG. 18A

FIG. 18B

FIG. 18C





FIG. 18D

FIG. 18E

FIG. 18F




FIG. 18G

FIG. 18H

FIG. 18I




FIG. 19

FIG. 20A




FIG. 20B




FIG. 21A





FIG. 21B






FIG. 22A




FIG. 22B




FIG. 22C




FIG. 22D



FIG. 23A



FIG. 23B




FIG. 24A




FIG. 24B




FIG. 25A




FIG. 25B




FIG. 26A




FIG. 26B




FIG. 26C



FIG. 26D




FIG. 27A




FIG. 27B




FIG. 28A




FIG. 28B




FIG. 29A




FIG. 29B




FIG. 30A




FIG. 30B




FIG. 31

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

- **WEN ; KESARI.** *Central Brain Tumor Registry*, 2008 [0003]
- **ZACH et al.** *PLOS One*, 2012 [0021]

专利名称(译)	用于分析组织的磁共振图		
公开(公告)号	EP2988668A1	公开(公告)日	2016-03-02
申请号	EP2014789048	申请日	2014-04-24
[标]申请(专利权)人(译)	特尔哈肖梅尔医学研究基础设施和服务有限公司 特拉维夫大学拉莫特有限公司		
申请(专利权)人(译)	TEL HASHOMER医学研究基础设施和服务有限公司. 拉莫特AT特拉维夫大学LTD.		
当前申请(专利权)人(译)	TEL HASHOMER医学研究基础设施和服务有限公司. 拉莫特AT特拉维夫大学LTD.		
[标]发明人	MARDOR YAEL ZACH LEOR GUEZ DAVID LAST DAVID DANIELS DIANNE		
发明人	MARDOR, YAEL ZACH, LEOR GUEZ, DAVID LAST, DAVID DANIELS, DIANNE		
IPC分类号	A61B5/05 A61B5/00 A61B6/00 A61B5/055 G01R33/28 G01R33/48 G01R33/56 G06T7/00		
CPC分类号	A61B5/0042 A61B5/055 A61B5/4842 A61B5/4848 A61B5/7275 A61B2576/026 G01R33/5601 G01R33/5608 G06T7/0016 G06T2207/10096 G06T2207/30016 G06T2207/30096 G16H30/40 G16H40/40 G16H40/63 A61K31/166 A61K31/555 A61K31/7068 A61K2300/00 G01R33/281 G01R33/4806		
代理机构(译)	博尔特WADE TENNANT		
优先权	61/815343 2013-04-24 US		
其他公开文献	EP2988668B1 EP2988668A4		
外部链接	Espacenet		

摘要(译)

公开了用于操作MRI的装置。该装置包括：用于操作MRI扫描仪以执行MRI扫描的控制器；用于在造影剂给药后的预定时间间隔的开始和结束时分别接收第一和第二MRI扫描的输入；减法图形成形器，用于通过分析扫描来形成来自第一和第二MRI扫描的减影图，以区分组织间的对比间隙慢于对比度累积的群体，以及间隙比累积快的群体；和输出，以提供人口分布的指示。控制器被配置为在造影剂施用后执行第一扫描至少五分钟且不超过二十分钟并且执行第二扫描使得预定时间段是至少二十分钟。